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 Depression predicts increased risk of coronary artery disease and type 2 diabetes, and 
the metabolic syndrome (MS) is a putative link between depression and these diseases.  There 
are no prospective studies of the effect of major depression on risk for the MS.  This study 
examined the cross-sectional and longitudinal relationship of major depression with the MS, 
central adiposity, and insulin resistance (IR), over a period of 6 years.  Data were drawn from the 
“Study of Women’s Health Across the Nation”, an ongoing, multi-site investigation of 
perimenopausal women. The sample included 421 women (34% Black), ages 42-52 (M = 45.6 + 
2.5) from the ancillary Mental Health Study of the participants from the Pittsburgh site.  Major 
depression diagnosis (lifetime history and current), other diagnoses (anxiety disorders, substance 
abuse / dependence) and antidepressant use were collected annually via the SCID-IV.  The MS 
was measured at baseline and bi-annually thereafter; WC and IR were assessed annually.  
Health behaviors included smoking (annually), and physical activity and diet (baseline).  Logistic 
regression and survival analyses examined the odds/risk of developing the MS over the course of 
the study in the full sample and in women free of the MS at baseline.  Generalized Estimating 
Equations (GEE) examined the relationship between depression (time-varying) and the MS (time-
varying) over the course of the study.  Exploratory analyses were conducted to examine whether 
associations were independent of demographics, diabetes, and other diagnoses, and to examine 
the association of depression with WC.  Baseline depression predicted marginally greater odds of 
having the MS over the course of the study (cumulative index) in the full sample, independent of 
covariates.  Women with baseline depression showed a trend for increased risk of developing the 
MS; this effect was not significant.  GEE analyses showed no significant concurrent associations 
 iii
between depression and the MS across time, suggesting that depression and the MS did not 
“track” together over time.  Finally, baseline depression predicted greater WC at the final visit, 
although this was reduced after controlling for age and race.  Findings suggest that major 
depression may be an important predictor of the prevalence and incidence of the MS in women.   
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1. INTRODUCTION 
 
1.1 OVERVIEW 
 
The metabolic syndrome is a cluster of anthropometric, metabolic and hemodynamic perturbations that 
have been linked to increased risk for Type 2 diabetes (Grundy, Brewer, Cleeman, Smith, & Lenfant, 
2004), cardiovascular morbidity and mortality, and all-cause mortality (Ford, 2005b; Hansen, 1999; 
Sundstrom et al., 2006; Trevisan, Liu, Bahsas, & Menotti, 1998).  To date, no consensus has been 
reached as to the definition of the metabolic syndrome.  However, abnormal insulin or glucose regulation, 
dyslipidemia, central adiposity or obesity, and hypertension are consistently included in the most widely 
accepted definitions of the metabolic syndrome, proposed by the World Health Organization (WHO) 
(Alberti & Zimmet, 1998), the U.S. National Cholesterol Education Program Adult Treatment Panel III 
(ATP III)  and the International Diabetes Foundation (IDF) (Alberti, Zimmet, & Shaw, 2005).  It is 
hypothesized that visceral / central adiposity and insulin resistance / glucose intolerance are most likely 
the key components (Grundy et al., 2005; Miranda, DeFronzo, Califf, & Guyton, 2005), and affect risk via 
a number of physiological mechanisms, including nonesterified fatty acid liberation and adipokine (e.g., 
adiponectin) production (Carr et al., 2004), independent of obesity and other risk factors (Egan, Greene, 
& Goodfriend, 2001; Janssen, Katzmarzyk, & Ross, 2002).  Nevertheless, some evidence exists that the 
convergence of these risk factors together represents a single cohesive syndrome which elevates one’s 
risk for disease (Pladevall et al., 2006; Shen et al., 2003).  Age-adjusted prevalence estimates for the 
metabolic syndrome in adults range from approximately 35% (using ATP III criteria) to approximately 40% 
(using IDF criteria), depending on the definition of impaired fasting glucose (Ford, 2005a).  As a prevalent 
condition and important predictor of disease across race, gender, and age groups, the metabolic 
syndrome provides a unique opportunity for identifying high-risk populations and preventing the 
progression of more serious diseases.  However, despite the potential implications of the metabolic 
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 syndrome for overall health and disease prevention, the etiology of the metabolic syndrome remains 
unclear. 
Interest in the role that psychological factors may play in the development and progression of the 
metabolic syndrome developed largely out of the extensive literature documenting the relationship 
between psychological variables and various disease outcomes, including coronary heart disease (CHD) 
and Type 2 diabetes, as well as the work of Bjorntorp and colleagues suggesting an association between 
chronic stress, visceral adiposity, and the metabolic syndrome (for reviews, see Bjorntorp, 2001; Bjorntorp 
& Rosmond, 1999).  Studies of psychological characteristics and disease have shown that anger / 
hostility (Krantz & McCeny, 2002; Miller, Smith, Turner, Guijarro, & Hallet, 1996; Williams et al., 2000) and 
some forms of clinical anxiety (Kubzansky, Kawachi, Weiss, & Sparrow, 1998), predict cardiovascular 
morbidity and mortality, although contradictory findings have been reported (Everson et al., 1997; Leon, 
Finn, Murray, & Bailey, 1988; Rozanski, Blumenthal, & Kaplan, 1999).  More consistent findings have 
been reported for depression, such that depressive illness as well as depressive symptoms predict 
increased risk for coronary disease and cardiovascular mortality (for reviews, see Grippo & Johnson, 
2002; Joynt, Whellan, & O'Connor, 2003; Musante & Treiber, 2000; Wulsin, 2004) .  Moreover, several 
meta-analytic reviews suggest that depression contributes a modest, but significant, independent risk for 
incident coronary disease (Rugulies, 2002; Wulsin & Singal, 2003), with one review showing that clinical 
depression was a stronger predictor of disease onset than depressive symptoms alone (Rugulies, 2002).  
Similar findings have been reported in the diabetes literature (for reviews, see Kawakami, Takatsuka, 
Shimizu, & Ishibashi, 1999; Musselman et al., 2003), such that depressive illness (Eaton, Armeniain, 
Gallo, Pratt, & Ford, 1996; Kawakami et al., 1999) and depressive symptomatology (Arroyo et al., 2004; 
Carnethon, Kinder, Fair, Stafford, & Fortmann, 2003) are associated with increased risk for incident Type 
2 diabetes.  
Despite substantial evidence for a role of depression in the pathogenesis of CHD and Type 2 
diabetes, relatively few studies have directly addressed the relationship between depression and the 
metabolic syndrome.  The existing literature is limited mostly to investigations of the association between 
depression and individual components of the metabolic syndrome, particularly central or visceral adiposity 
and insulin resistance.  The majority of these studies have demonstrated a cross-sectional association of 
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 depression or depressive symptoms with these particular components of the metabolic syndrome, 
especially in young adults; although, a few failed to find significant cross-sectional associations in middle-
aged women.  Prospective data are mixed, with several studies showing a positive association with 
central adiposity or insulin resistance, and others failing to find prospective associations with levels of 
central adiposity.  Although these studies provide indirect support for the contention that depression is 
related to components of the metabolic syndrome, they are limited by mainly cross-sectional data and do 
not provide information about the relationship between depression and the clustering of these 
components to form the metabolic syndrome.    
To our knowledge, only four studies have examined the relationship between depression or 
depressive symptoms and the metabolic syndrome in its entirety.  Two studies, conducted with cross-
sectional data, showed that depressive symptoms in men (McCaffery, Niaura, Todaro, Swan, & Carmelli, 
2003) or a history of major depressive illness in women, but not men (Kinder, Carnethon, Palaniappa, 
King, & Fortman, 2004) was associated with increased risk for the metabolic syndrome.  However, a third, 
cross-sectional study of depressive symptoms in young adults failed to find an association with central 
adiposity or the metabolic syndrome (Herva, Rasanen et al., 2006).  In the only prospective study of the 
relationship between depression and the metabolic syndrome, Raikkonen, Matthews, and Kuller (2002) 
showed that women with higher baseline depressive symptoms had elevated risk for developing the 
metabolic syndrome over time, providing preliminary support for an association between depression and 
the metabolic syndrome in middle-age.   
In aggregate, the data from these converging lines of research provide some preliminary 
evidence for the hypothesis that depression is related to elevated risk for the metabolic syndrome, 
particularly in women.  However, the current literature is marked by several limitations.  First, most of the 
data are cross-sectional and therefore provide no information about the direction of the relationship 
between depression and the metabolic syndrome.  Moreover, self-report measures of depressive 
symptoms do not elucidate the nature of the relationship between depression, particularly depressive 
illness, and the metabolic syndrome.  Despite the relevant physiological aberrations reported to 
accompany clinical depression and the growing evidence for a dose-response relationship between 
depression and CHD (Wulsin, 2004), only one study has investigated the relationship between clinical 
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 depression and the metabolic syndrome (Kinder et al., 2004).  Although this study provides preliminary 
evidence for a cross-sectional relationship between a history of major depressive illness and the 
metabolic syndrome in women, the data provide no information about direction of the association and do 
not account for the potential effect of time.  We are unaware of any study to date that has prospectively 
examined the relationship between depressive illness and the metabolic syndrome.   
Thus, the purpose of the current study is to investigate the cross-sectional and longitudinal 
relationship of depressive illness with the metabolic syndrome in a sample of women undergoing the 
menopausal transition.  Importantly, the longitudinal nature of the data and the repeated measurements 
over time will permit closer examination of the association between clinical depression and the metabolic 
syndrome over time and test the hypothesis that depression precedes the metabolic syndrome.  Given 
the evidence to suggest that insulin resistance and central adiposity are likely the core components of the 
metabolic syndrome, we will also examine the relationship of depression with waist circumference and an 
indicator of insulin resistance.  Finally, we will explore whether these associations vary by race or 
menopausal status, and we will evaluate health behaviors as a possible mechanism linking depression 
with the metabolic syndrome.  A model describing the hypothesized association between depression and 
the metabolic syndrome, as well as potential mediating and moderating pathways, is presented in Figure 
1.   
Prior to outlining the hypotheses and methodology of the current study, this paper will provide a 
historical context and rationale by presenting a brief summary of the following topics: (1) a description of 
the metabolic syndrome, its central physiological aberrations, and some of the factors believed to 
contribute to its development; (2) the history of psychosocial factors and the metabolic syndrome, 
emphasizing the evidence for a link between psychological indicators and the metabolic syndrome; (3) 
the relationship between depression and the purported core components of the metabolic syndrome, 
namely, central adiposity and insulin resistance; (4) available studies of depression and the metabolic 
syndrome and limitations of the current literature; (5) potential moderating factors of the relationship 
between depression and the metabolic syndrome.  
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Figure 1: Model of the association between depression and the metabolic syndrome   
 
 
 
 
 
 
Central  
Adiposity 
 Depression
 
 
Behavioral: 
Diet 
Activity, Smoking 
Vulnerability 
Factors 
(Race, Gender) 
 
Metabolic 
Syndrome
Vulnerability Factors 
(Race, Gender) 
Biological: 
HPA, SNS, Serotonin 
Insulin  
Resistance
5 
 1.2 THE METABOLIC SYNDROME 
 
 
1.2.1 Background  
 
Interest in the metabolic syndrome developed out of an observation that certain cardiovascular risk 
factors frequently co-occurred, and that these risk factors were both independently and cumulatively 
related to cardiovascular health (Reaven, Abbasi, & McLaughlin, 2004).  Since that time, there has been 
a growing body of evidence for an association between the metabolic syndrome and disease, particularly 
CHD and Type 2 diabetes (Grundy, Hansen, Laaksonene, et al., 2002), independent of traditional risk 
factors (e.g., obesity).  Although there is some debate about the best definition of the metabolic 
syndrome, the two most widely accepted definitions classify the metabolic syndrome based on the 
presence of three or more of the following physiological aberrations: abdominal / visceral adiposity, insulin 
resistance, hypertension, and dyslipidemia (Expert Panel on Detection, 2001).  Given the insalubrious 
effects of insulin resistance and central adiposity on cardiovascular and metabolic health (Lapidus & 
Bengtsson, 1988; Larsson, 1988; Pouliot et al., 1992; Pyorala, Savolainen, Kaukola, & Haapakoski, 
1985), some researchers have postulated that these constituents drive the heightened risk for disease 
(Anderson et al., 2001; DeFronzo & Ferrannini, 1991; Despres & Marette, 1994; Reilly & Rader, 2003).  
However, there is also fairly robust support for the assertion that the concurrence of the multiple risk 
factors represents one cohesive syndrome, and the syndrome itself is the best predictor of disease 
(DeFronzo & Ferrannini, 1991; Expert Panel on Detection, 2001; Shen et al., 2003).   
It is hypothesized that psychological factors, in concert with or independent of genetic 
vulnerabilities (Bouchard, Despres, & Mauriege, 1993; Freeman, Mansfield, Barrett, & Grant, 2002; Groop 
& Ortho-Melander, 2001), may contribute to the pathogenesis of the metabolic syndrome through both 
physiological (e.g., hypothalamic-pituitary-adrenal (HPA) axis, sympathetic-adrenal-medullary (SAM) 
system) (Bjorntorp & Rosmond, 1999; Landsberg, 1999) and behavioral (e.g., diet, physical inactivity) 
pathways.  Because of the extensive literature documenting the relationship between psychological 
variables and various disease outcomes, particularly those for which the metabolic syndrome is a putative 
risk factor, attention has turned to the role that psychological factors may play in the pathogenesis of the 
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 metabolic syndrome.  Notably, a better understanding of the relationship between psychological factors 
and the metabolic syndrome may identify the metabolic syndrome as a link between psychological factors 
and disease, especially CHD and Type 2 diabetes (Bjorntorp, 1990, 1991).   
 
1.2.2 Psychosocial Factors and the Metabolic Syndrome  
 
Literature on the relationship between the metabolic syndrome and psychological factors has evolved 
from several converging lines of research, including the chronic stress literature and studies of the Type A 
behavior pattern.  For example, Bjorntorp has written fairly extensively about the hypothesis that chronic 
stress is related to the development of central adiposity and the metabolic syndrome (Bjorntorp, 1991, 
1993, 1997, 1999, 2001; Bjorntorp & Rosmond, 1999).  The assertion in these papers is that chronic 
exposure to stressors (including a variety of psychosocial and psychological factors) activates the HPA 
axis and related “stress centers” which, in turn, contribute to preferential fat deposition in the abdominal 
area and subsequent development of insulin resistance and other features of the metabolic syndrome.  
While relevant literature provides some empirical support for an association between chronic stress and 
central adiposity (e.g. Epel et al., 2000), psychological factors are often indiscriminately combined with 
other psychosocial vulnerabilities and discussed only within the context of stress.   
 Based on the hypothesis that the Type A construct confers increased risk for the development of 
CHD, a limited number of studies have investigated the association between Type A behavior and 
features of the metabolic syndrome (Keltikangas-Jarvinen, Raikkonen, & Hautanen, 1996; Keltikangas-
Jarvinen, Raikkonen, Hautanen, & Herman, 1996).  However, given the results of several epidemiological 
investigations which failed to find support for a relationship between the Type A construct and CHD 
(Dembroski, MacDougall, Williams, Haney, & Blumenthal, 1985; Matthews & Haynes, 1986; Shekelle et 
al., 1985), the majority of the focus shifted from the global Type A construct to more specific 
investigations of hostility and anger, as subsequent investigations revealed that these attributes may be 
the most critical components of the Type A behavior pattern (Dembroski et al., 1985). 
Recent investigations of the relation of the metabolic syndrome with psychological factors have 
focused on more specific indicators of psychological functioning.  For instance, several studies have 
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 shown that anger, hostility, and anxiety are cross-sectionally associated with central adiposity (Kaye, 
Folsom, Jacobs, Hughes, & Flack, 1993; Niaura et al., 2000; Niaura et al., 2002; Scherwitz et al., 1992; 
Wing, Matthews, Kuller, Meilahn, & Plantinga, 1991) or insulin resistance (Surwit et al., 2002; Vitaliano, 
Scanlan, Krenz, & Fujimoto, 1996), the physiological aberrations hypothesized to be at the heart of the 
metabolic syndrome.  There is also some evidence for a prospective relationship of anger or hostility with 
increased central adiposity (Raikkonen, Matthews, & Kuller, 1999; Raikkonen, Matthews, Kuller, Reiber, 
& Bunker, 1999) and risk for the full metabolic syndrome over time (Raikkonen, Matthews, & Salomon, 
2003).  However, results are not entirely consistent, as some studies have shown no association (Ravaja, 
Keltikangas-Jarvinen, & Viikari, 1996) or an inverse or bi-directional relationship (Nelson, Palmer, 
Pedersen, & Miles, 1999; Raikkonen et al., 2002). 
   
 
1.3 WHY DEPRESSION? 
 
1.3.1 Depression and Health 
 
Numerous studies conducted with population-based samples have consistently demonstrated that a 
history of major depressive disorder confers increased risk for the development of CHD and Type 2 
diabetes (Eaton et al., 1996), independent of other psychiatric disorders and traditional risk factors 
including age, race, SES, and body mass index (BMI).  Furthermore, preliminary evidence suggests that 
metabolic dysregulation in Type 2 diabetes may improve upon treatment of depression with non-
pharmacological therapy (Lustman, Griffith, Freedland, Kissel, & Clouse, 1998).  Studies conducted with 
measures of depressive symptomatology in healthy individuals have been less consistent, with some 
showing that symptoms predict CHD and clinical coronary events (Dallman, 1993; Grippo & Johnson, 
2002; Joynt et al., 2003) as well as incident Type 2 diabetes (Golden et al., 2004; Kawakami et al., 1999), 
and others failing to find such associations (Saydah, Brancati, Golden, Fradkin, & Harris, 2003; Wulsin, 
2004).  Evidence seems to be stronger for diagnostic measures of depressive illness, compared to less 
specific self-report measures of depression which often capture “distress” rather than clinical depression 
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 (Wulsin, 2004).  There is some evidence for a graded relationship between depression and coronary 
disease, such that elevated relative risks for disease have been found for major compared to subclinical 
depression and depressive symptoms; however, data on the effect of cumulative exposure to depression 
or depressive symptoms are inconclusive (Rudisch & Nemeroff, 2003).   
 
1.3.2 Depression and Central Adiposity  
 
Further support for a role of depression in the metabolic syndrome comes from studies of the association 
between depression and central adiposity, one of the putative risk factors for the metabolic syndrome.  
Findings from the majority of cross-sectional studies conducted with non-clinical populations support a 
positive association between depressive symptoms and central adiposity in men and women (Ahlberg et 
al., 2002; Haukkala & Uutela, 2000; Katz et al., 2000; Lee, Kim, Beck, Lee, & Oh, 2005; Petrlova, 
Rosolova, Hess, Podlipny, & Simon, 2004; Wing et al., 1991), although inconsistent data have been 
reported (Cota, Vicennati, Ceroni, Morselli-Labate, & Pasquali, 2001; Herva, Laitinen et al., 2006; 
Marniemi et al., 2002).  Three studies have investigated the relationship between depressive symptoms 
and central adiposity over time; one demonstrated that depressive symptoms predicted increased levels 
of central adiposity in healthy women, but not men (Nelson et al., 1999), and a second study, conducted 
with a diabetic sample, showed that depressive symptoms predicted greater WHR in women, and change 
in depressive symptoms predicted change in WHR in women and men (Lloyd, Wing, & Orchard, 1996).  
While, the third study, conducted with healthy postmenopausal women, showed that depressive 
symptoms were cross-sectionally associated with greater WC at baseline and overall depressive 
symptoms were associated with overall greater WC across time, changes in depression were not 
associated with changes in WC (Raikkonen, Matthews, & Kuller, 1999).   
Results of the majority of cross-sectional studies of clinically depressed young adults showed that 
depression was associated with greater levels of central adiposity in men and women, (Eskandari et al., 
2005; Miller, Freedland, Carney, Stetler, & Banks, 2003), and greater visceral adiposity in women (Kahl et 
al., 2005; Thakore, Richards, Reznek, Martin, & Dinan, 1997), relative to healthy controls.  In contrast, 
two studies of middle-aged women have failed to show differences in central (Hach, Ruhl, Klotsche, 
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 Klose, & Jacobi, 2006) or visceral adiposity between women with and without major depression (Weber-
Hamann et al., 2006), suggesting that the relationship between depression and adiposity may not be 
consistent across all ages.  Interestingly, when depressed patients in the latter study were divided into 
“normocortisolemic” and “hypercortisolemic” groups, the “normocortisolemic” patients actually exhibited 
lower visceral fat mass, compared to controls.  In the only longitudinal investigation, Weber-Hamann et al. 
(2006) showed that older men and women diagnosed with a major depressive episode exhibited a 
marginally greater percent increase in VAT over time as compared to controls, independent of BMI and 
weight change; however, patients did not have significantly greater mean VAT than controls at baseline or 
follow-up.  It is important to note that all patients in this study underwent six weeks of “standardized” in-
patient pharmacological treatment for depression followed by out-patient care; follow-up measures were 
taken approximately 14 months following in-patient treatment.  In aggregate, these studies suggest that 
depression is cross-sectionally associated with greater levels of central adiposity, particularly in young 
adults.  However, given the potential age differences in the relationship between clinical depression and 
body fat distribution, as well as the inconsistencies between longitudinal findings with depressive 
symptoms and clinical depression, further research is needed to clarify the relationship between clinical 
depression and central adiposity in middle-aged samples and across time.    
 
1.3.3 Depression and Insulin Resistance 
 
Since the mid-1960’s researchers have been documenting an association of major depression with 
aberrant metabolic responsiveness to glucose tolerance (GTT) and insulin tolerance tests (ITT), two 
indicators of metabolic control.  For instance, previous research has shown that patients with major 
depression exhibit impaired insulin responses during ITTs (Casper, Davis, Pandey, Garver, & 
Dekirmenjian, 1977; Sachar, Finkelstein, & Hellman, 1971) and GTTs (Mueller, Heninger, & McDonald, 
1968).  Until recently however, few studies have included healthy controls or other comparison groups, 
preventing any definitive conclusions about associations between depression and the insulin / glucose 
system.   
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 Several case-control studies have explored the relationship between clinical depression and 
proxies for insulin resistance.  Using mostly indicators of glucose tolerance or fasting glucose, the majority 
of studies have shown that patients diagnosed with major depressive disorder exhibit greater metabolic 
impairment than healthy (Okamura et al., 2000; Weber, Schweiger, Deuschle, & Heuser, 2000; Winokur, 
Maislin, Phillips, & Amsterdam, 1988; Wright, Jacisin, Radin, & Bell, 1978) or psychiatric controls (Nathan, 
Sachar, Asnis, Halbreich, & Halpern, 1981); the only study to assess insulin resistance directly showed 
similar impairment in women with comorbid major depression and borderline personality disorder, 
compared to psychiatric controls (Kahl et al., 2005).  Data on the concurrent association of depressive 
symptoms with proxies for insulin resistance in healthy samples suggest that depressive symptoms may 
be associated with indicators of impaired glucose tolerance in White men (Ahlberg et al., 2002; 
Raikkonen, Keltikangas-Jarvinen, & Hautanen, 1994) but may not be associated with fasting levels in 
women (Huerta, Mena, Malacara, & Diaz de Leon, 1995).  Results of cross-sectional studies that 
assessed insulin resistance more directly are mixed; one demonstrated an association with depressive 
symptoms in young adult men (Timonen et al., 2006), although another showed an association in young-
adult women but not men (Suarez, 2006).  Variation across studies may be attributable, in part, to the 
specificity and reliability of the assessment of depression and insulin resistance, as well as the use of 
clinical versus community-based samples.  Importantly, the only longitudinal study of depression and 
insulin resistance showed that depressive symptoms predicted greater insulin resistance in a multi-ethnic 
sample of women, although this association was mediated by physical activity and central adiposity 
(Everson-Rose et al., 2004).  In aggregate, these studies suggest that depression, especially depressive 
illness, may be associated with dysregulation of the insulin / glucose system; however, further studies are 
needed to explore the relationship of depressive illness with specific indicators of insulin resistance and 
examine this association over time.   
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 1.4 DEPRESSION AND THE METABOLIC SYNDROME 
 
1.4.1 Depressive Symptoms 
 
Two cross-sectional studies have investigated the relationship between depressive symptomatology and 
the metabolic syndrome.  McCaffery, Niaura, Todaro, Swan, and Carmelli (2003) used structural equation 
modeling to investigate the genetic versus environmental contributions to the covariation of depressive 
symptoms with the metabolic syndrome in White male monozygotic (MZ) and dizygotic (DZ) twin pairs.  
Depressive symptoms were assessed by the CES-D, a standardized self-report measure.  The metabolic 
syndrome was represented by the common variance among BMI, WHR, mean arterial pressure (MAP), 
triglycerides, and glucose.  Results showed that depressive symptoms were positively associated with 
WHR and the overall clustering of metabolic syndrome risk factors.  However, the second study failed to 
find an association between depressive symptoms, assessed by the Hopkins Symptom Checklist-25, and 
odds of having the metabolic syndrome (defined according to ATP III criteria) in young adult men and 
women (Herva, Rasanen et al., 2006).           
 In the only prospective study of depression and the metabolic syndrome, Raikkonen, Matthews, & 
Kuller (2002) examined the effect of depressive symptomatology and other psychological factors on risk 
for developing the metabolic syndrome in a sample of 425 pre-, peri-, and post-menopausal women taken 
from the Healthy Women’s Study.  Depressive symptoms were assessed using the BDI; the metabolic 
syndrome was defined according to NHLBI criteria.  At baseline, women with the metabolic syndrome had 
greater levels of depressive symptomatology, supporting a cross-sectional association between 
depressive symptoms and the metabolic syndrome.  Notably, women with higher baseline depression 
scores had greater risk for developing the metabolic syndrome during the 7.4-year follow-up period, 
although changes in depression scores were not related to risk for the metabolic syndrome.  Presence of 
the metabolic syndrome did not affect depressive symptoms.  There was no effect of health behaviors on 
any of these relationships, although postmenopausal status was a significant predictor of the metabolic 
syndrome at baseline.   
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  In aggregate, these studies suggest that depressive symptoms are related to the metabolic 
syndrome in its entirety, although the data are not entirely consistent.  While the findings of Raikkonen et 
al., (2002) support the notion that depression may be related to pathogenesis of the metabolic syndrome, 
this study provides no information about depressive illness.  Given the preliminary evidence for a graded 
relationship between depression and disease, as well as evidence for metabolic dysregulation in patients 
with depressive disorders, a better understanding of the nature of the relationship between clinical 
depression and the metabolic syndrome is warranted. 
 
1.4.2 Depressive Illness 
 
To our knowledge, only one study has investigated the relationship between depressive illness and the 
metabolic syndrome, and no study has examined the effect of depression treatment on the metabolic 
syndrome.  In a nationally representative, cross-sectional sample of men and women (NHANES III), aged 
17 to 39 years, Kinder et al. (2004) examined the association between lifetime history of major depression 
and the metabolic syndrome.  Lifetime history of depression was treated as a dichotomous variable 
according to whether or not a participant had a major depressive episode at any point up to and including 
the time of assessment.  The authors found that a history of a depressive episode in women was 
associated with approximately twice the odds of having the metabolic syndrome as compared to women 
who had no depression, independent of age, race, education, and health behaviors.  This association was 
not significant in men.  Interestingly, post-hoc exploratory analyses showed that neither the number of 
depressive episodes over one’s lifetime, age of first episode, nor the presence of a current episode were 
significantly associated with the prevalence of the metabolic syndrome.  However, it is unclear what cutoff 
was used to differentiate each of these categories.  Although results from this study suggest that clinical 
depression may be important for understanding the metabolic syndrome, the cross-sectional nature of the 
study precludes any conclusions about the direction of the association between depressive illness and 
the metabolic syndrome.   
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 1.5 FACTORS THAT MAY INFLUENCE THE RELATIONSHIP BETWEEN DEPRESSION AND THE 
METABOLIC SYNDROME 
 
1.5.1 Gender 
 
There is a fairly extensive literature showing that depression is more prevalent in women worldwide 
(Weissman et al., 1996) and in community samples throughout the United States (Piccinelli & Wilkinson, 
2000; Weissman, Livingston, & Leaf, 1991).  There is also some evidence to suggest that these 
differences extend to clinical samples with coronary artery disease (Rudisch & Nemeroff, 2003) and Type 
2 diabetes (Musselman et al., 2003).  Data from the few studies which examined gender differences in 
the association between depression and central adiposity are mixed.  For example, Nelson et al. (1999) 
demonstrated that depressive symptoms predicted increased central adiposity 5-7 years later in middle-
aged women, but not men.  However, Herva, Laitinen, et al. (2006) found that depressive symptoms were 
associated with greater concurrent central adiposity in men, but not women, and Haukkala and Uutela 
(2000) found that depressive symptoms were associated with greater central adiposity in men and 
women.  Only one study has examined gender differences in the association with insulin resistance, and 
results of this study showed that depressive symptoms were positively associated with insulin resistance 
in women, but not men (Suarez, 2006).  Most importantly, the only study to investigate gender differences 
using the metabolic syndrome in its entirety showed an association with clinical depression in women, but 
not men (Kinder et al., 2004), suggesting that depression may be a more important predictor for women 
than men.      
 
1.5.2 Race 
 
Indirect evidence from converging lines of research suggests that race may influence the relationship 
between depression and the metabolic syndrome.  For instance, race differences in visceral adiposity, 
insulin sensitivity, and incidence and prevalence of Type 2 diabetes are well documented (Davidson, 
2001; Perry et al., 2000), and several studies have demonstrated that the relationship between central 
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 adiposity and risk for disease in middle-aged and older women differs between Blacks and Whites 
(Berman et al., 2001; Dowling & Pi-Sunyer, 1993).  There is some evidence to suggest that, compared to 
Whites, Blacks may be more likely to exhibit comorbid depression and Type 2 diabetes (Blazer, Moody-
Ayers, Craft-Morgan, & Burchett, 2002), and depressed Black women may be at greater risk for 
developing Type 2 diabetes, independent of central adiposity and other risk factors (Everson-Rose et al., 
2004).  However, the study by Everson-Rose et al. (2004) showed that depressive symptoms predicted 
greater insulin resistance in Black and White women.  No study has explored race differences in the 
association between depression and central adiposity.  To date, only Kinder et al. (2004) have examined 
race differences in the association between a measure of depression and the metabolic syndrome; they 
found that the association did not differ between Blacks and Whites.  However, further research is needed 
to explore whether race affects the association between depression and the metabolic syndrome or its 
core components over time. 
 
1.6 SUMMARY 
 
Evidence from converging lines of research on depression and disease, as well as studies of depression 
and adiposity or insulin resistance, provide preliminary support for the hypothesis that depression confers 
increased risk for the metabolic syndrome.  Nevertheless, only four studies have directly investigated the 
relationship between depression and the metabolic syndrome in its entirety.  While the results the majority 
of these studies suggest that depression is associated with the metabolic syndrome, they are limited in 
several ways.  First, three of the studies were cross-sectional, precluding any conclusions about the 
direction of the association.  Although results of the study by Raikkonen et al. (2002) suggest that 
depressive symptoms precede the metabolic syndrome, prospective studies conducted with diverse 
samples and measures of depressive illness are needed to better understand the relationship between 
depression and the metabolic syndrome.  Moreover, no study has prospectively explored the effect of 
behavioral lifestyle factors on the association between depressive illness and the metabolic syndrome.   
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 1.7 PURPOSE OF THE CURRENT STUDY AND HYPOTHESES 
 
The primary purpose of the current study is to investigate the relationship between clinical depression and 
the metabolic syndrome in a sample of Black and White middle-aged women.  To our knowledge, this 
study will be the first to prospectively examine the association of major depression with the metabolic 
syndrome.  The hypotheses of this study are: 
 
1.7.1 Primary Hypotheses - Metabolic Syndrome 
 
Hypothesis 1:  Major depression (lifetime history or current) at baseline will be associated with the 
presence of the metabolic syndrome at baseline.    
 Hypothesis 2a:   Major depression (lifetime history or current) at baseline will be associated with 
increased odds of having the metabolic syndrome at any point during the study (baseline - 05).   
 Hypothesis 2b:   Major depression (lifetime history or current) at baseline will be associated with 
increased odds of having the metabolic syndrome at any point during the five-year follow-up period (visits 
01, 03, or 05) in individuals who are free of the metabolic syndrome at baseline.   
 Hypothesis 3:  In participants who are free of the metabolic syndrome at baseline, women with a 
diagnosis of major depression (lifetime history or current) at baseline will have increased risk for 
developing the metabolic syndrome across the five-year follow-up period compared to women without a 
diagnosis of major depression at baseline.   
Hypothesis 4: A lifetime history or current diagnosis of major depression (at each visit) will be 
associated with greater odds of having the metabolic syndrome (at each visit), across the six-year study 
period.   
Hypothesis 5:  Predicated associations between depression and the metabolic syndrome will be 
independent of race, menopausal status, diabetes diagnosis, antidepressant medication use, and other 
psychiatric diagnoses. 
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 Hypothesis 6:  Provided that we confirm an association between depression and the metabolic 
syndrome, we will explore whether behavioral lifestyle factors (physical activity, smoking, diet) account for 
this relationship. 
 
1.7.2 Secondary Hypotheses - Central Adiposity and Insulin Resistance  
 
We expect that the association of depression with central adiposity and insulin resistance will follow a 
similar pattern as Hypotheses 1, 2 and 4.  That is, we anticipate that a history of depression will be 
associated with greater central adiposity and insulin resistance at baseline and across time. 
Hypothesis 7:  Major depression (lifetime history or current) at baseline will be associated with 
greater central adiposity and greater insulin resistance at baseline and follow-up visit 05.   
Hypothesis 8:  A lifetime history or current diagnosis of major depression (at each visit) will be 
greater central adiposity and insulin resistance (at each visit) across the 6-year study period.   
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2. METHOD 
 
2.1  STUDY OVERVIEW 
 
The data used in the current study were drawn from a larger study titled “Study of Women’s Health 
Across the Nation” (SWAN).  SWAN is an ongoing, multi-site community based cohort investigation 
designed to prospectively examine the biological and psychosocial correlates of the menopausal 
transition, as well as their potential influence on subsequent health and disease risk factors (Sowers et 
al., 2000).  The present investigation focused specifically on data taken from participants in the ancillary 
Mental Health Study conducted in three of the seven sites of SWAN, in which psychiatric interviews were 
used to obtain information on lifetime and current psychiatric disorders.  Analyses for the current study 
were based on data collected at baseline and annually thereafter for five additional years, for a total of six 
visits.  Because six-year, prospective psychiatric diagnostic data were available for only one of the three 
sites (Pittsburgh), this study was limited to data from that site.   
 
2.2 STUDY DESIGN AND SAMPLE 
 
2.2.1 Overview of Parent Study (SWAN) and the ancillary Mental Health Study 
 
The original SWAN study design consisted of an initial, cross-sectional phase (used primarily to identify 
eligible participants) and a longitudinal cohort study.  The sampling procedures and design of the multi-
site SWAN parent study have been described previously (Sowers et al., 2000).  Participants at the 
Pittsburgh site were recruited using random digit dialing (RDD) and a voter’s registration list.  Eligibility 
criteria for the longitudinal SWAN study included being aged 42-52, having an intact uterus, having had at 
least one menstrual period in the previous 3 months, no use of reproductive hormones in the previous 3 
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 months, and self-identifying with one of the site’s designated race / ethnic groups, i.e. at Pittsburgh 
African-Americans or Caucasians.  At the Pittsburgh site, a total of 463 women completed the baseline 
visit for the SWAN parent study.  Following the Institutional Review Board’s guidelines for human 
research, written informed consent was obtained at the beginning of the study.   
At study entry and annually thereafter as part of the parent investigation, all participants 
completed a standard assessment protocol, including interviewer-administered and self-administered 
questionnaires assessing medical, reproductive, and menstrual history; psychosocial factors and physical 
and psychological symptoms; and behavioral and lifestyle characteristics.  Interviewers for the 
interviewer-administered questionnaires were trained and certified at baseline and annually thereafter.  
Initial training involved watching a training video, reviewing the interviewer manual and study instruments, 
and completing an audiotaped interview with a volunteer.  This audiotaped interview was subsequently 
sent to the Coordinating Center, along with a supervisor and self-evaluation form, for evaluation and 
approval.  Annually thereafter, interviewers were required to be recertified via yearly training or evaluation 
of an audiotaped practice interview. 
As part of the parent study, blood was drawn at baseline and bi-annually (visits 01, 03, and 05) 
for the measurement of lipids and lipoproteins, insulin, and glucose; anthropometric measures (e.g., blood 
pressure, height, weight, and waist circumference) were taken at baseline and annual follow-up visits.  
Blood samples for biological markers (i.e., lipids and lipoproteins, insulin, and glucose) were obtained 
between days two and five of the follicular phase of the menstrual cycle and after a 12 hour fast, ideally 
before 10:00 am.  After completion of the blood draw, all samples were maintained at 4°C until spun and 
separated, and then frozen at -20° C and shipped on dry ice to the central laboratory (Medical Research 
Laboratories (MRL), Highland Heights, KY) for analysis (certified by the National Heart Lung and Blood 
Institute, Centers for Disease Control Lipid Standardization Part III program (Myers, Cooper, Winn, & al., 
1989).  The interassay coefficients of variation for the blood assay measures were as follows: cholesterol 
(2.5%), HDL (3.5%), insulin (8.0%), and glucose (2.0%).  To ensure accuracy and consistency of sample 
collection and processing, each phlebotomist or technician was evaluated annually via observation of the 
following: collection of blood samples; labeling, processing, and storing specimens; shipping procedures; 
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 appropriate use of data collection forms; and site freezer and refrigerator temperatures, back-up systems, 
and alarm systems.   
Quality control procedures for anthropometric and blood pressure measurements included initial 
technician certification, annual re-certification, on-site monitoring, continuous training and review, and 
continuous data monitoring.  Initial certification involved following a standardized protocol for height, 
weight, blood pressure, pulse, and waist and hip circumference measurements on two volunteers, 
followed by identical measurements on the same two volunteers, performed by a certified technician.  
Differences between measurements conducted by the two technicians could not differ by more than 1 cm 
for height, waist, and hip circumference; 2 mm Hg for both blood pressure measurements; and 1 kg for 
weight measurements. 
As part of the Mental Health Study, diagnostic psychiatric interviews were conducted at baseline 
and annually thereafter to determine a lifetime history (baseline only), past year (follow-up visits only), 
and current psychiatric diagnosis at each visit.  Interviews were administered by trained clinical staff 
(clinicians with an MD or PhD degree, a master’s degree in psychology, social work, or a related field, or 
a degree in psychiatric nursing) within 9 months of the SWAN baseline assessment and again at follow-
up visits 01-05 to obtain information on diagnoses that had occurred since the prior study visit.  
Interviewers completed a multistep certification process which included a training session with a Biometric 
Institute member, review of videotaped practice interviews by a psychiatric epidemiologist, and review 
and certification of the videotape by the Biometrics Institute.  Interrater reliability scores for lifetime SCID 
diagnoses (at baseline), assessed in a systematic sample of 12 audiotapes, ranged from good to very 
good for a variety of psychiatric diagnoses: Kappa = 0.81 for major depressive disorder, 0.78 for 
substance dependence, and 0.82 for anxiety disorders.  Interrater reliability scores for the follow-up visits, 
assessed using a sample of 49 interviews, were similar:  Kappa = 0.88 for major depressive disorder, 
0.73 for subsyndromal depression, and 0.83 for anxiety disorders.  There were too few cases of 
substance abuse and dependence at the follow-up visits to reliably determine Kappas for these 
diagnoses. 
Of the 443 women who participated in the Mental Health Study at the Pittsburgh site, 429 
provided baseline data for the metabolic syndrome and psychiatric diagnoses.  Eight of these women had 
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 a lifetime history of bipolar disorder and / or a manic episode over the 6-year study time-period, and were 
consequently excluded from the sample.  The remaining 421 women were included in the current 
analyses. 
  
 
2.3 MEASURES 
 
 
2.3.1 Psychological Measures  
 
Psychiatric Disorders.  Psychiatric diagnoses were assessed annually from baseline (lifetime and current) 
through year five, for a total of six years.  Psychiatric diagnoses, including diagnoses of major and minor 
depression, were determined by the Structured Clinical Interview for Diagnosis of DSM-IV Axis I 
Disorders (SCID-IV/NP).  The SCID is a semistructured diagnostic interview designed to enable a trained 
interviewer to establish lifetime and current diagnoses of psychiatric disorders according to the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition (American Psychiatric Association, 1994).  The 
SCID has been used with various ethnic groups and its reliability has been demonstrated in numerous 
studies (Spitzer, Williams, Gibbon, & First, 1992: Williams et al., 1992).    
For the purpose of the current study, a lifetime history of depression was defined as the presence 
of a major depressive episode prior to the SWAN baseline assessment.  From this point forward, the term 
baseline depression” will be used to refer to a lifetime history of a major depressive episode or a current 
major depressive episode at the baseline visit.  Past year depression at each follow-up visit was defined 
as the presence of a major depressive episode or subthreshold recurrence within the past year; current 
depression at each visit was defined as the presence of a major depressive episode or subthreshold 
recurrence currently or within the month preceding that visit.  For the purpose of this study, depression at 
each visit will include a major depressive episode or subthreshold recurrence currently or within the year 
prior to that visit.  The term “cumulative depression” will be used to refer to a major depressive episode at 
any point up through and including the current visit.   Table 1 presents the number of participants at 
baseline and each follow-up visit who met criteria for a major depressive episode or subthreshold 
recurrence, as well as those who met criteria for any type of depressive episode (i.e., major depressive 
episode, subthreshold recurrence, minor depressive episode, dysthymia).  As seen in Table 1,  
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 Table 1: Sample characteristics at baseline and follow-up visits 
 
 
Number of participants in final sample 421 
  
Number in original sample 443 
  
Number with complete data at visit 00 429 
  
Number with bipolar disorder or manic episode 8 
  
Age Range (years) 42-52 (M = 45.6 + 2.5) 
  
Self-Identified Ethnicity 277 White / Caucasian 
 144 Black / African-American 
  
Education (years) M = 15, SD = 2.2 
  
Menopausal Status Pre / early peri Late peri Post / surgical   
Visit 00  (n = 418) 418 (99.3%) 0 0 
Visit 01 (n = 384) 330 (85.9%) 15 (3.9%) 7 (1.8%) 
Visit 02 (n = 371) 276 (74.4%) 26 (7.0%) 19 (5.1%) 
Visit 03 (n = 373) 231 (61.9%) 29 (7.8%) 54 (14.5%) 
Visit 04 (n = 364) 182 (50.0%) 39 (10.7%) 86 (23.6%) 
Visit 05 (n = 340) 136 (40.0%) 43 (12.6%) 122 (35.9%) 
  
Depression Major or Subthreshold 
Recurrence
Major, Minor, or 
Dysthymia  
Lifetime history / current at 00 150 (35.6%) 212 (50.4%) 
Visit 00 past year / current only (n=415) 48 (11.6%) N/A 2 
Visit 01 (n = 384) 52 (13.5%) 68 (24.0%) 
Visit 02 (n = 386) 52 (13.5%) 65 (16.8%) 
Visit 03 (n = 377) 47 (12.5%) 60 (14.3%) 
Visit 04 (n = 364) 44 (10.5%) 53 (12.6%) 
Visit 05 (n = 353) 48 (11.4%) 56 (13.3%) 
  
Lifetime history / current anxiety disorder at visit 
00 (n=421) 
101 (24%) 
  
Lifetime history / current alcohol at visit 00 
(n=420) 
54 (12.9 %) 
  
Lifetime history / current drug at visit 00 (n = 
421) 
35 (8.3%) 
  
Antidepressant Use (baseline n = 421)  
Lifetime history / current at visit 00 3 64 (15.2%) 
Visit 01 (n = 384) 75 (19.5%) 
Visit 02 (n = 386) 69 (17.9%) 
Visit 03 (n = 377) 67 (17.8%) 
Visit 04 (n = 364) 73 (20.1%) 
Visit 05 (n = 353) 83 (23.5%) 
Note: 1 M = mean, SD = standard deviation; 2 Data for last occurrence of minor depression and dysthymia 
not available; 3 A total of 64 participants had a lifetime history of antidepressant use, 33 of whom reported 
current antidepressant use at baseline. 
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 approximately 35% of the sample met criteria for a lifetime history or current diagnosis of major 
depression at baseline, and approximately 50% of the sample met criteria for major depression, minor 
depression, or dysthymia at baseline. 
 Other psychiatric data included any history of an Axis I anxiety disorder (including panic disorder, 
social phobia, specific phobia, agoraphobia, obsessive-compulsive disorder, or generalized anxiety 
disorder), and any history of alcohol or substance abuse or dependence (see Table 1).   
 Antidepressant Use.  Data on lifetime history of antidepressant use, as well as past year and 
current use at each visit, were collected annually during the SCID interview (see Table 1).  For the 
purpose of the current investigation, baseline antidepressants will refer to a lifetime history of  
 
2.3.2 Self-Administered and Interviewer-Administered Questionnaires 
 
Sociodemographic and Descriptive Variables  
 Ethnicity was self-identified as African-American or Caucasian; 34% of study participants 
identified themselves as Black / African-American.  Education was measured continuously as the highest 
grade level.  At baseline, menopausal status was categorized according to bleeding patterns, defined as 
premenopausal (no decrease in predictability of menses onset in prior 12 months) or early 
perimenopausal (menstrual period in the past three months, but less predictable periods in the last 12 
months).  For the purpose of the current study, menopausal status at each of the follow-up visits was 
coded as one of the following four categories:  premenopausal (menstrual period within past 3 months 
and no change in regularity) or early perimenopausal (menstrual period within past 3 months but self-
reported change in regularity); late perimenopausal (menstrual period within the past year but not in the 
past 3 months); postmenopausal (hysterectomy, oopherectomy, or no bleeding in the 12 months prior to 
the interview for that visit); or unknown due to HRT use (see Table 1 for a summary of sample 
characteristics).   
Health Behaviors   
 Table 2 presents the frequencies and distributions for the health behaviors and select biological 
variables at baseline and subsequent follow-up visits.  
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 Table 2: Frequencies and distributions of health behaviors and biological variables 
 
 
Variable N (%) 1 
  
Smoking  
Visit 00 (n = 418) 78 (18.7%) 
Visit 01 (n = 384) 63 (16.4%) 
Visit 02 (n = 366) 61 (16.7%) 
Visit 03 (n = 363) 54 (14.9%) 
Visit 04 (n = 358) 55 (15.4%) 
Visit 05 (n = 338) 47 (13.9%) 
  
Physical Activity (Visit 00 only) M = 8.0 SD = 1.7 Skew = 0.06 
  
Total kcal (Visit 00 only) M = 1899.6 SD =  761.9 Skew = 1.39 
  
% kcal from fat (Visit 00 only) M = 33.8 SD = 7.4 Skew = 0.27 
  
% kcal from carb (Visit 00 only) M = 51.0 SD = 8.3 Skew = 0.11 
  
Metabolic Syndrome (MS) Present 
Visit 00 (n = 421) 85 (20.2%) 
Visit 01 (n = 365) 82 (22.5%) 
Visit 03 (n = 322) 72 (22.4%) 
Visit 05 (n = 286) 60 (21.0%) 
Ever from 00-05 (n = 324) 2 123 (38% of women with available data; 29% of original sample) 
Incident through 05  38 (9% of original sample; 11.3% of women free of MS at baseline) 
  
Waist Circumference (cm)  
Visit 00 (n = 415) M = 87.9 SD = 15.2 Skew = 0.88 
Visit 01 (n = 379) M = 88.7 SD = 15.6 Skew = 0.88 
Visit 02 (n = 353) M = 89.8 SD = 15.4 Skew = 0.89 
Visit 03 (n = 337) M = 89.9 SD = 15.7 Skew = 1.0 
Visit 04 (n = 325) M = 90.3 SD = 15.1 Skew = 0.75 
Visit 05 (n = 313) M = 89.9 SD = 15.6 Skew = 0.81 
    
HOMA-IR 3  
Visit 00 (n = 412) M = 2.8 SD = 3.8 Skew = 6.8 
Visit 01 (n = 357) M = 3.0 SD = 4.7 Skew = 8.7 
Visit 03 (n = 319) M = 3.1 SD = 5.2 Skew = 9.9 
Visit 05 (n = 269) M = 3.0 SD = 4.7 Skew = 7.7 
    
BMI (kg/m2) at Visit 00 (n = 416)  M = 28.7, SD = 6.4 
  
Diabetes (fasting glucose > 126 
mg/dl or taking medication for 
diabetes) 
 
 
Present 
Visit 00 (n = 417) 25 (6.0%) 
Visit 01 (n = 361) 25 (6.9%) 
Visit 03 (n = 321) 18 (5.6%) 
Visit 05 (n = 283) 20 (7.1%) 
Ever from 00-05 (n = 283) 25 (8.8%) 
Note: 1 M = mean, SD = standard deviation  2 If missing and didn’t develop metabolic syndrome, counted 
as missing. 3 HOMA-IR values for all visits were transformed using square-root transformations.  
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  Smoking status. Cigarette smoking was determined at all visits by asking women to respond to 
three items on the amount smoked and quit date, if applicable.  At each visit (baseline – 05), a 
dichotomous smoking variable (yes/no) was created to indicate current smoking status. 
 Diet.  Diet was assessed at baseline using a modification of the Block food frequency 
questionnaire (FFQ) (Block et al., 1986; Block, Thompson, Hartman, Larkin, & Guire, 1992), described in 
detail elsewhere (Huang et al., 2002).  The interview-administered questionnaire included 103 items 
covering the majority of foods that are nutrient contributors to the diets of the ethnic groups in SWAN.  
The interview yielded a variety of scores; this study focused on total kilocalories (including alcohol) and 
percent kilocalories from fat and carbohydrates.   
 Physical Activity.  Physical activity was measured at baseline using a self-administered 
questionnaire based on the Baecke physical activity questionnaire (Baecke, Burema, & Fritijers, 1982).  
Responses to a series of questions on typical physical activity in the past year were used to create three 
distinct physical activity indices corresponding to three domains (based on the frequency, intensity, and 
duration of the following activities: sports and exercise, active living, and household / caregiving); possible 
scores for each index range from 1-5.  A continuous measure of total activity was then created by 
summing these three indices.    
 
2.3.3 Biological Measures 
 
Waist circumference and blood pressure were measured at baseline through follow-up visit 05.  
Triglycerides, high-density lipoprotein cholesterol (HDL-C), insulin, and glucose were assessed at 
baseline and follow-up visits 01, 03, and 05.  Because data for some of the components of the metabolic 
syndrome were not collected at all time points, data for the metabolic syndrome were available for a total 
of four time points (baseline, 01, 03, and 05).   
 Metabolic Syndrome.  For the current study, a participant was classified as having the metabolic 
syndrome if she met three or more of the following criteria: 
1) Abdominal Obesity: Waist circumference >88cm. 
2) Hypertriglyceridemia: Triglyceride value > 150 mg/dl.   
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 3) Low HDL cholesterol: HDL value < 50 mg/dl.   
4) Hypertension: SBP > 130 or DBP > 85 mmHg or taking “blood pressure pills”. 
5) Impaired fasting glucose: fasting glucose > 110 mg/dl (or having ever been classified 
as diabetic)  
 A variable was then created for each visit to indicate whether, using the criteria above, a 
participant has the metabolic syndrome at that visit, irrespective of her metabolic syndrome classification 
at all previous visits.  A “cumulative index” of the metabolic syndrome was also created to indicate 
whether a participant had the metabolic syndrome at any point during the study period (baseline – visit 
05).  A participant’s cumulative metabolic syndrome status was coded as “present” if she had the 
metabolic syndrome at the current or any previous visit; status was coded as “absent” if she did not meet 
criteria at the current or any previous visit; status was coded as missing if she had missing data at the 
current or any previous visit and no current or previous diagnosis of the metabolic syndrome.  As seen in 
Table 2, approximately 20% of the women were classified as having the metabolic syndrome at baseline; 
29% of the women were classified as ever having had the metabolic syndrome (cumulative index) over 
the course of the study. 
Central Adiposity.  Waist circumference (cm) was used as the index of central adiposity.  Waist 
circumference (WC) was measured at the level of the natural waist, defined as the narrowest part of the 
torso as seen from the anterior aspect.  In cases where a waist narrowing was difficult to identify, the 
measure was taken at the smallest horizontal circumference in the area between the ribs and the iliac 
crest.  The mean WC for this sample at baseline was 87.9cm (SD = 15.2; see Table 2).      
Triglycerides / HDL Cholesterol.  All lipid, lipoprotein and apolipoprotein fractions were analyzed 
on EDTA-treated plasma (Steiner, Frieidel, Bremner, & Stein, 1981; Warnick & Albers, 1978).  Total 
cholesterol and triglycerides were analyzed by enzymatic methods on a Hitachi 747 analyzer (Boehringer 
Mannheim Diagnostics, Indianapolis, IN) as previously described (Steiner et al., 1981), and HDL-C was 
isolated using heparin-2M manganese chloride (Warnick & Albers, 1978).   
Blood Pressure.  Blood pressure was measured according to a standardized protocol, with 
readings taken on the right arm, with the respondent seated and feet flat on the floor for at least 5 minutes 
prior to the measurement.  Respondents had not smoked or consumed any caffeinated beverage within  
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 30 minutes of blood pressure measurement.  Appropriate cuff size was determined based on arm 
circumference.  A standard mercury sphygmomanometer was used to record systolic (SBP) and diastolic 
(DBP) pressures at the first and fifth phase Korotkoff sounds.  Two sequential blood pressure values were 
completed, with a minimum two-minute rest period between measures.  
Insulin and Glucose.  Insulin and glucose were measured from the blood specimens obtained 
after a 12-hour fast and drawn during days 2-5 of the follicular phase of the menstrual cycle.  Serum 
insulin was measured using radioimmunoassay (RIA) (DPC Coat-A-Count, Los Angeles, CA) procedure 
and monitored as part of the monthly quality assurance program provided by the Diabetes Diagnostic 
Laboratory at the University of Missouri.  Glucose was measured using a hexokinase-coupled reaction on 
a Hitachi 747-200 analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN).  
Insulin Resistance.  Insulin resistance was calculated using the revised Homeostasis Model 
Assessment (HOMA-IR) equation (Wallace, Levy, & Matthews, 2004).  The HOMA-IR is considered an 
acceptable surrogate measure of insulin resistance for use in studies in which more invasive measures of 
insulin resistance are unfeasible or excessive (Bonora et al., 2000; Wallace & Matthews, 2002).  It is 
based on fasting plasma glucose and insulin concentrations and is derived from a computer algorithm, it 
accounts for variations in hepatic and peripheral glucose resistance, and it is calibrated to insulin assays 
that are currently available.  Greater HOMA-IR values indicate decreased insulin sensitivity or insulin 
resistance; the mean HOMA-IR value at baseline was 2.8 (SD = 3.8; see Table 2).   
Body Mass Index.  Body mass index (BMI) was calculated as weight in kilograms divided by 
height in meters squared.  Height was measured without shoes using a fixed stadiometer.  Weight was 
measured without shoes, and in light indoor clothing, using a either a digital or balance beam scale; 
scales were calibrated monthly.  The mean BMI at baseline was 28.7 kg/m2 (SD = 6.4; see Table 2). 
Diabetes.  Diabetes was ascertained at baseline and visits 01, 03, and 05; a woman was 
classified as having diabetes at that visit if she reported taking “insulin or pills for sugar in her blood” or 
had a fasting glucose level > 126 mg/dl.  At baseline, 25 women met these criteria for diabetes, 18 of 
whom reported taking “insulin or pills for sugar in her blood”.     
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 2.4  DETAILED HYPOTHESES AND ANALYTIC PLAN 
 
2.4.1 Data Management and Statistical Software 
 
All data from the SWAN parent study (i.e., physical measures, biological assays, health behaviors, 
sociodemographic and descriptive variables) were centrally stored at the SWAN Coordinating Center, 
located at the University of Pittsburgh.  Data for biological assays were sent electronically from the SWAN 
core laboratory (MRL) after completion of specimen analysis and results were entered into an oracle 
database followed by conversion for use in SAS.  Data for all other physical measures, health behaviors, 
sociodemographic and descriptive variables were entered into an oracle database at the Coordinating 
Center and converted for use in SAS.  The data management system at the Coordinating Center 
automatically checks for missing data and violated validation ranges each time a form is entered.  An edit 
report is generated each time possible errors are detected, and completed reports are reviewed to correct 
the error or confirm the accuracy of the data. 
All psychiatric data collected during the SCID interviews were recorded and coded in the SCID 
booklet by the interviewer who reviewed it for accuracy and consistency with diagnoses.  Final diagnoses 
were coded on SCID Summary Score Sheets (SSS). The interviewer transferred all data that were not 
diagnoses (e.g., medication use) onto custom designed SCID Data Entry Forms (DEF).  A research 
associate conducted a visual review of the SSS/DEF to check for inconsistencies and then documented 
them in a Manual Edit Report; inconsistencies were resolved by the interviewer prior to data entry. Two 
computers equipped with the data entry software were used for entry, verification, logic and range 
checks, and editing of SCID data. The SCID data were stored on a local network drive for use by SWAN 
personnel only; data were backed up on a daily basis.    
Data for the current analyses were obtained from the Coordinating Center (parent study data) or 
the local network drive (SCID data) and subsequently merged and converted for use in SPSS and Stata 
Statistical Software (Stata Corporation, College Station, Texas; release 9.0).   
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 2.4.2 Data Reduction and Preliminary Analyses 
 
Preliminary analyses were conducted to examine the distribution of all continuous variables (see Table 2); 
highly skewed variables were transformed as indicated.  Inter-correlations among baseline covariates, 
depression (lifetime history / current at baseline), and the metabolic syndrome (baseline and cumulative 
through visit 05) were calculated using Pearson’s r (continuous variables), point-biserial (continuous and 
dichotomous), and Phi-correlation (dichotomous) coefficients.      
 Preliminary analyses were also conducted to examine and compare the characteristics of 
participants with a baseline diagnosis of lifetime history / current major depression; minor depression or 
dysthymia (lifetime history / current); and no depression.  While it was originally proposed to define 
depression as the occurrence of any type of depression (major, minor, dysthymia) to increase the power 
for the proposed analyses, preliminary analyses showed that mean waist circumference, prevalence of 
the metabolic syndrome, and prevalence of a major depressive episode across time did not differ 
between women with a history or current diagnosis of minor depression or dysthymia at baseline and 
women with no depression.  Moreover, it appeared that women with a lifetime history or current diagnosis 
of major depression at baseline had a greater prevalence of the metabolic syndrome at baseline and the 
follow-up visits, and they also had a greater number of major depressive episodes (or subthreshold 
recurrences) at each of the follow-up visits, suggesting that it would be inappropriate to combine all 
women with any depression diagnosis (see Table 1 in Appendix A for percentages).  To be thorough, 
analyses for Hypotheses 1 and 2 were conducted with depression defined both as major depression only 
and as any depression (major, minor, dysthymia).  Consistent with the preliminary sample comparisons, 
the addition of minor depression and dysthymia weakened the association between depression and the 
metabolic syndrome (see Tables 2 and 3 in Appendix A for results).  Hence, the decision was made to 
define depression as the occurrence of a major depressive episode or subthreshold recurrence only; all 
further analyses were conducted with depression defined in this manner, and depression hereafter will 
refer to major depression / subthreshold recurrence only.   
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 2.4.3 Primary Hypotheses - Metabolic Syndrome 
 
Hypothesis 1:  Major depression (lifetime history or current) at baseline will be associated with the 
presence of the metabolic syndrome at baseline.  In comparison to subjects with no lifetime history or 
current diagnosis of major depression at baseline, subjects with major depression were expected to have 
greater frequency of the metabolic syndrome at baseline (Figure 2).  Chi-square tests were conducted to 
examine the association of baseline depression (dichotomous) with presence of the metabolic syndrome 
(dichotomous) at baseline.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypothesis 2a:   Major depression (lifetime history or current) at baseline will be associated with 
increased odds of having the metabolic syndrome at any point during the study (baseline - 05) 
(Figure 3a).  A series of stepwise logistic regression analyses were used to examine the odds of having 
the metabolic syndrome during any visit (“cumulative index” of the metabolic syndrome at visit 05) based 
No D D
Figure 2: Hypothesis 1: Baseline association 
between lifetime history / current depression 
and the metabolic syndrome 
Note: No D = No major depression; D = Major 
depression 
 
MS
Lifetime / 00 
Visit 00 
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 on baseline depression (dichotomous).  In the first set of analyses, depression was entered on step 1 and 
baseline age and race on step 2.  In all further analyses, depression, race, and baseline age were 
entered on step 1, followed by the planned covariates that showed a significant univariate correlation (p < 
.10) with baseline depression or the metabolic syndrome (baseline or cumulative through 05).  
 
 
 
 
Figure 3a: Hypothesis 2a: Association between lifetime history / current depression at baseline and 
cumulative index of the metabolic syndrome through visit 05 
No D D 
Note: No D = No major depression; D = Major depression; MS = Metabolic syndrome 
 
 
Hypothesis 2b:   Major depression (lifetime history or current) at baseline will be associated with 
increased odds of developing the metabolic syndrome at any point during the 5-year follow-up 
period (visits 01, 03, or 05) in individuals who are free of the metabolic syndrome at baseline 
(Figure 3b).  Analyses paralleled those described in hypothesis 2a, except the sample was limited to 
those women who were free of the metabolic syndrome at baseline. 
 
 
Lifetime / 00 
MS 
Any visit 00-05
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Figure 3b: Hypothesis 2b: Association between lifetime history / current depression at baseline and 
incident metabolic syndrome during follow-up visits 
No D D 
MS 
Lifetime / 00 
Any visit 01-05 
Note: No D = No major depression; D = Major depression; MS = Metabolic syndrome 
 
 
 
Hypothesis 3:  In participants who are free of the metabolic syndrome at baseline, women with a 
diagnosis of major depression (lifetime history or current) at baseline will have increased risk for 
developing the metabolic syndrome across the five-year follow-up period compared to women 
without a diagnosis of major depression at baseline (Figure 4).  In participants who were free of the 
metabolic syndrome at baseline, unadjusted and adjusted Cox proportional hazards models were used to 
calculate risk of developing the metabolic syndrome across the follow-up visits based on baseline 
depression diagnosis (lifetime history / current; dichotomous).  This analytic procedure accounts for 
missing data, censoring, and unequal follow-up time; it allows for continuous and categorical covariates; 
and it allows for comparisons between groups without making assumptions about the underlying 
distribution of the hazard function (Cleves, Gould, & Gutierrez, 2004). 
 Univariate analyses were first conducted with baseline depressive status in the model, followed 
by multivariate analyses adjusting for baseline age and race.  Baseline menopausal status was entered 
as a covariate to initial models to confirm that associations were independent of menopausal status.  
Covariates for fully adjusted models were chosen based on results of preliminary correlational analyses;  
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No D D
MS 01 
MS 03 
MS 05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Hypothesis 3: Cox proportional hazard model of the effect of baseline 
depression on risk of developing the metabolic syndrome at a follow-up visit  
Note: No D = No major depression; D = Major depression; MS = Metabolic syndrome 
 
 
all planned covariates which were related to depression (baseline) or the metabolic syndrome (baseline 
or cumulative index at 05) at the p< .10 level were entered into the models.  Visit year was used as the 
unit of analysis, and the incident (failure) date was defined as the year of the follow-up visit during which 
the participant was first classified as having the metabolic syndrome.  The proportional hazards 
assumption was evaluated and confirmed via a test for zero-slope of Schoenfeld residuals, indicating that 
the log hazard ratio function is constant over time (Schoenfeld, 1982).    
Hypothesis 4: A lifetime history or current diagnosis of major depression or subthreshold 
recurrence across time will be associated with increased odds of having the metabolic syndrome 
across the 6-year study period.  The relationship between depression and the metabolic syndrome 
across time was examined using Generalized Estimating Equations (GEE).  GEE is a type of general 
linear model (GLM) used for clustered data which adjusts for the within-subject correlation present among 
repeated observations over time (Liang & Zeger, 1986; Zeger, Liang, & Albert, 1988).  Unlike many other 
methods used to analyzed repeated measures data (e.g. repeated measures ANOVAs), GEE can handle 
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 longitudinal data on subjects with observations that are varying in number and are unequally spaced.  
This method is suitable for the longitudinal analysis of both dichotomous and continuous covariates and 
outcomes, and it allows for time-varying independent and dependent variables.  This modeling technique 
tests the association between a diagnosis of depression and the presence of the metabolic syndrome at 
each visit, and subsequently collapses across visits.  More specifically, coefficients are calculated through 
a series of logistic regression models at each time-point, corrected for the correlation among time points, 
and then subsequently collapsed across all time-points to generate a final coefficient.  The final 
regression coefficient represents an average of the “between-subjects” effects (comparing women with 
depression to women with no depression) and “within-subjects” effects (comparing the effect when a 
woman is depressed to the effect when that woman is not depressed).    
To test the hypothesis that depression (at visits 00, 01, 03, and 05) was associated with greater 
odds of having the metabolic syndrome (at visits 00, 01, 03, and 05; Figure 5a), a GEE model was 
estimated with a binomial outcome (presence / absence of metabolic syndrome) distribution and a logit 
link.  The link function specifies a nonlinear transformation of the predicted values and is used to model 
responses when the relationship between the independent and dependent variables is thought to be 
nonlinear (Hardin & Hilbe, 2003).  Based on preliminary examination of correlations between repeated 
measurements, an exchangeable working correlation structure (assumes that the correlations between 
subsequent measurements are similar, irrespective of the length of the time interval) was adopted to 
account for the correlation among repeated observations.  The GEE model produces an odds ratio and 
95% confidence interval for the metabolic syndrome based on major depression diagnosis (yes / no), 
controlling for age at each visit, accounting for the effects of time.  For these analyses, depression and 
age were treated as time-varying independent variables (IV), and the metabolic syndrome was treated as 
a time-varying dependent variable (DV).  An interaction between depression and age was also entered 
into the model to examine whether the odds of having the metabolic syndrome with age were greater for 
participants with depression.      
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Figure 5a:  Hypothesis 4: GEE model of associations between depression and the metabolic syndrome 
across time 
Note: No D = No major depression or subthreshold recurrence at that visit; D = Major depression or 
subthreshold recurrence at that visit; MS = Metabolic syndrome 
 
 
 
A second, “time-lag” model was produced to test the hypothesis that depression precedes the metabolic 
syndrome by estimating the odds of having the metabolic syndrome (dichotomous) at time tx, based on a 
cumulative index of depression at time tx-1 (presence / absence of a major depressive episode at any 
point up to and including that visit; see Figure 5b), controlling for time and age at each visit (concurrent 
with the metabolic syndrome).  This model estimates an odds ratio and 95% confidence interval showing 
the association between a cumulative index of a prior major depressive episode (at any point up to and 
including the previous visit; for lifetime, visit 00, 02, and 04) and the presence of the metabolic syndrome 
at the current visit for each visit (visits 00, 01, 03, and 05), and subsequently collapses across visits to 
generate the final coefficient.  For this model, depression was treated as a type of time-varying DV, in that 
women were allowed to move from “not depressed” to “depressed”; however, once classified as 
depressed, they stayed in this category for the remainder of the visits.  As with the previous model, age 
was treated as a time-varying IV, and the metabolic syndrome was treated as a time-varying DV.  Finally, 
as previously described, this model was estimated with a binomial outcome distribution (presence / 
absence of metabolic syndrome), and an exchangeable correlation structure was adopted to account for 
the correlation among repeated observations.   
No D 
D 
No D D D 
MS MS MS MS 
D 
No D 
D 
No D D 
Time 
Lifetime / 00                 01                02             03                  04             05 
             00                  01    03            05 
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Figure 5b.  Hypothesis 4b: GEE time-lag model of associations between cumulative depression at the 
previous visit and the metabolic syndrome at the following visit across time 
Note: No D = No major depression or subthreshold recurrence up through and including the visit; D = 
Major depression or subthreshold recurrence up through and including the visit; MS = metabolic 
syndrome 
 
 
2.4.4 Exploratory Analyses 
 
Hypothesis 5:  Predicated associations between depression and the metabolic syndrome will be 
independent of race, menopausal status, diabetes diagnosis, antidepressant medication use, and 
other psychiatric diagnoses.  As described above, race was entered into models 2-4 to examine 
whether the association between depression and the metabolic syndrome was reduced; menopausal 
status (baseline for models 2 and 3; at each visit for model 4) was entered into the same models to 
confirm that the associations were independent of menopausal status.  Analytically, categories of 
menopausal status were compared to premenopause.  Analyses were rerun excluding participants with 
diabetes at baseline (n = 25) to confirm that the associations were independent of diabetes.1   
Chi-square tests were used to test for differences between individuals with and without 
depression (lifetime history / current diagnosis) on baseline diagnoses of anxiety, drug, and alcohol use 
disorders (all lifetime history / current) and baseline antidepressant use (lifetime history / current use).  
Variables that differed significantly between the two groups (p < .10) were added to examine their 
influence on the association between depression and the metabolic syndrome.   
 Hypothesis 6:  Health behaviors (physical activity, diet, and smoking) will be added to 
significant models to explore whether the association between depression and the metabolic 
syndrome is reduced.  Preliminary analyses were conducted to explore the association of physical 
activity, total caloric intake, percent calories from fat, percent calories from carbohydrates, and smoking 
No D No D No D 
D 
MS MS MS MS 
             00         01                        03           05 
D 
No D 
Time 
D 
   Lifetime        Lifetime - 00      Lifetime - 02               Lifetime - 04 
D 
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 (baseline only) with baseline depression (lifetime history / current) and the metabolic syndrome (baseline 
and cumulative through visit 05).  Variables which were correlated with depression or the metabolic 
syndrome at the p < .10 level were entered into the models to examine whether the association between 
major depression and the metabolic syndrome was reduced.       
 
2.4.5 Secondary Hypotheses - Central Adiposity and Insulin Resistance  
 
Hypothesis 7:  Major depression (lifetime history or current) at baseline will be associated with 
increased central adiposity and increased insulin resistance at baseline and follow-up visit 05.  
Univariate and multivariate (controlling for baseline age and race) General Linear Model (GLM) ANOVAs 
were used to test for significant differences between depression groups at baseline (dichotomous) in 
mean WC and HOMA values at baseline and visit 05 (Figures 6 and 7).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:  Hypothesis 7: Baseline  
No D D
WC / IR 
Lifetime / 00
Visit 00 
associations between lifetime history /  
current depression and waist circumference 
or insulin resistance 
Note: No D = No major depression 
D = Major depression;   
WC = waist circumference; IR = insulin resistance 
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No 
D
WC / IR 
Lifetime / 00 
Visit 05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Hypothesis 7: Association between lifetime history / current depression at 
baseline and waist circumference or insulin resistance at visit 05  
Note: No D = No major depression; D = Major depression; WC = waist circumference; 
IR = insulin resistance 
 
 
 
Hypothesis 8:  Based on the results of the above GLMs, significant group differences in mean 
waist circumference will be present throughout the study, such that depression (major depression 
or subthreshold recurrence) will be associated with higher waist circumference across time.  GEE 
was used to examine associations between depression (at each visit) and WC (at each visit) across the 
study period.  Waist circumference was treated as a continuous variable.  The GEE model was estimated 
with a Gaussian (normal) outcome distribution and an identity link; an exchangeable correlation structure 
was adopted to model the correlation among repeated observations.  The first model tested the 
hypothesis that depression (at each visit) is associated with greater WC (at each visit) across time (see 
Figure 8a).  For these analyses, depression and age were treated as time-varying independent variables 
(IV), and waist circumference was treated as a time-varying dependent variable (DV).  An interaction 
between depression and age was also entered into the model to examine whether changes in waist 
circumference with age were greater for participants with depression.  As with Hypothesis 4, this modeling 
technique tests the association between a diagnosis of depression and waist circumference at each visit 
by calculating unstandardized coefficients through a series of linear regression models at each time-point, 
corrected for the correlation among time points, and then subsequently collapsed across all time-points to 
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 generate a final showing the magnitude of the relationship between major depression (dichotomous) and 
WC, controlling for age at each visit. 
 
 
 
 
Figure 8a:  Hypothesis 8a: GEE model of associations between depression and waist circumference 
across time. 
            00                01                02               03                04                  05 
WC WC WC WC WC WC 
 Lifetime / 00              01                02               03                 04                05 
Time 
D 
No D 
D 
No D 
D 
No D 
D 
No D 
D 
No D 
D 
No D 
Note: No D = No major depression or subthreshold recurrence at that visit; D = Major depression or 
subthreshold recurrence at that visit; WC = Waist circumference 
   
 
 
A second, “time-lag” model was produced to test the hypothesis that depression precedes increased WC 
by examining associations between a cumulative index of depression at time tx-1 (presence / absence of a 
major depressive episode at any point up to and including that visit) and WC at time tx, controlling for age 
at each visit (concurrent with WC; see Figure 8b).  This model estimated unstandardized regression 
coefficients showing the magnitude of the longitudinal relationship between any prior major depressive 
episode (up to and including the visit; for lifetime, and visits 00 – visit 04) and WC at the current visit 
(visits 00 – 05), and subsequently collapses across visits to generate the final coefficient (see Figure 8b).  
For this model, depression was treated as a type of time-varying DV, in that women were allowed to move 
from “not depressed” to “depressed”; however, once classified as depressed, they stayed in this category 
for the remainder of the visits.  As with the previous model, age was treated as a time-varying IV, and 
waist circumference was treated as a time-varying DV.  As with the model described above, this model 
was estimated with a Gaussian (normal) outcome distribution and an identity link.  An exchangeable 
correlation structure was adopted to account for the correlation among repeated observations.   
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Figure 8b: Hypothesis 8b: GEE time-lag model of associations between cumulative depression at the 
previous visit and waist circumference at the following visit across time 
     Lifetime   Lifetime-00   Lifetime-01  Lifetime-02  Lifetime-03  Lifetime- 04      
            00                01                02               03                04                  05 
Time 
WC WC WC WC WC WC 
D 
No D 
D 
No D 
D 
No D 
D 
No D 
D 
No D 
D 
No D 
Note: No D = No major depression or subthreshold recurrence up through and including the visit; D = 
Major depression or subthreshold recurrence up through and including the visit; WC = waist 
circumference 
 
 
 
As described in Hypotheses 5 and 6, race and menopausal status were added to all models, and planned 
covariates that were significantly correlated with depression or the outcomes at baseline were entered 
into significant models to examine their effect on the relationship of depression with WC and HOMA-IR.   
Statistical Software.  Stata was used for the GEE and Cox models; SPSS was used for all other 
analyses. 
 
 
 
2.5  POWER ANALYSES 
 
Power calculations are not readily available or reliable for the type of survival model conducted herein, 
and no power calculations are available for the GEE models.  Thus, very conservative estimates of power 
were calculated for the basic analyses for this study.  However, calculations do not generalize to the more 
sophisticated models (e.g., Cox proportional hazards, GEE) and are not necessarily valid indicators of the 
power for these analyses.  For logistic regression analyses, power was computed using basic calculations 
for a logistic model based on a normal approximation.  With an alpha-level of .05, the power to detect 
differences between women with and without a lifetime history or current diagnosis of major depression at 
baseline in the odds of having the metabolic syndrome from baseline through follow-up visit 05 was 0.50.  
These calculations were based on the univariate analyses which were limited to the 324 women for whom 
there were no missing data.  The power to detect differences using the analyses which allow for missing 
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 data (i.e., GEE and Cox models), was expected to be larger.  In addition, the GEE model uses all 
available data from all participants and gains additional power by estimating both the “within-subject” and 
“between-subjects” effects and subsequently averaging them to create a single regression coefficient 
(Twisk, 2003).  Power calculations were conducted using Power and Precision 2.0 (Biostat, 2000). 
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3. RESULTS 
 
 
 
3.1  PRELIMINARY ANALYSES 
 
Preliminary analyses showed that HOMA-IR values at each visit were highly positively skewed (see Table 
2); values remained positively skewed (skewness = 2.11 - 3.55) after removing participants with diabetes.  
Thus, HOMA-IR values for the full sample were transformed by taking the log transformation of the 
original variable and transformed values were used in all further analyses.       
 Table 3 presents the inter-correlations among baseline covariates, depression (lifetime history / 
current at baseline), and the metabolic syndrome (baseline and cumulative through visit 05).  Presence of 
the metabolic syndrome at baseline and cumulatively through visit 05 were positively associated with 
antidepressant use, age, WC, diabetes, and percent caloric intake from fat (baseline metabolic syndrome 
only); the metabolic syndrome (baseline and cumulative 05) was negatively associated with baseline 
levels of physical activity scores.   
 Baseline WC was positively associated with being Black (vs. White), perimenopausal status (vs.  
premenopausal), a diagnosis of alcohol use / dependence, age, total caloric intake and percent caloric 
intake from fat, and diabetes status.  Greater WC was also associated with lower levels of physical 
activity and percent caloric intake from carbohydrates.  Baseline HOMA values were positively associated 
with percent caloric intake from fat and diabetes, and values were negatively associated with physical 
activity and percent caloric intake from carbohydrates. 
 As seen in Table 3, major depression at baseline was positively associated (p < .05) with a 
diagnosis of any anxiety disorder, drug abuse / dependence, alcohol use / dependence, antidepressant 
use, and years of education.  Table 4 presents the results of chi-square tests used to compare women 
with and without baseline depression (lifetime history / current) on frequency of other psychiatric 
diagnoses at baseline.  Compared to women with no lifetime history or current diagnosis of major 
42 
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depression at baseline, a greater percentage of women with baseline depression met criteria for a lifetime 
history or current diagnosis of drug abuse / dependence, alcohol abuse / dependence, and any anxiety 
disorder (all p’s < .05; see Table 4).  
 Table 3:  Inter-correlations among baseline values and the cumulative index of the metabolic syndrome at visit 05 (ever from visit 00 – 05) 
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MD …                    
Any D .74b …                   
Anxiety .15b .21b …                  
Drug .12a .11a .11a …                 
ETOH .16b .17b .07 .46b …                
Meds .36b .39b .07 .06 .11b …               
Age -.01c -.03c -.12a -.08 -.05 -.01 …              
Race -.05c -.08c -.04 .11a .02 -.15b -.03 …             
PA .01c .02c .00 .02 -.02 -.02 .00 -.21b …            
Kcal .01c -.01c -.01 .08 .07 .03 -.17b .14b .04 …            
Note:  MD = major depression; Any D = major depression, minor depression, or dysthymia; Anx = any anxiety disorder; Drug = drug abuse / 
dependence; ETOH = alcohol use / dependence; Meds = antidepressants; PA = physical activity; MS = metabolic syndrome; WC = waist 
circumference; DM = diabetes; MenStat = menopausal status. 
 a = p< .05, b = p< .01, c = p >.10 (only listed for depression & MS); point-biserial for dichotomous x continuous; phi-correlation for dichotomous x 
dichotomous. 
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Table 3:  (continued) 
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% fat .05c .04c .03 .02 .03 -.06 .05 .12a -.15b .09 …          
% carb -.03c -.03c .00 -.05 -.14b .06 -.03 .01 .08 .06 -.84b …         
Smoke -.01c -.02c -.07 .11a .22b .04 -.06 .07 -.05 .07 .10a -.12a …        
MS 0 .07c .06c -.02c .00c .08c .10a .15b .05c -.16b .06c .11a -.05c -.03c …       
MS 5 .10 .09c -.02c .06c .11 .12a .12a .10 -.22 b .05c .10 -.06c .07c .76b …      
HOMA -.05c -.02c -.05 .03 .00 .09 -.01 .05 -.19b .01 .10a -.11a -.09 .39b .33b …     
WC .04c .02c .06 .08 .16b .07 .12a .22b -.25b .10a .15b -.10a -.05 .57b .61b .38b …    
DM .00c .01c -.03 .07 .00 .12a .08 .09 -.17b .00 .13b -.11a -.10 b .46b .34b .69b .37b …   
Edu .11a .10a .08 -.04 -.05 .13b -.09 -.07 -.01 -.03 -.10a .09 -.17b -.05c -.09 .04 .00 .02 …  
Men 
Stat -.04
c -.04c -.00 -.11a -.04 -.04 -.06 .0c .02 .03 -.03 .02 -.08 .01c .00 .04 -.10a .02 .09 … 
Note: MD = major depression; Any D = major depression, minor depression, or dysthymia; Anx = any anxiety disorder; Drug = drug abuse / 
dependence; ETOH = alcohol use / dependence; Meds = antidepressants; PA = physical activity; MS = metabolic syndrome; WC = waist 
circumference; DM = diabetes; MenStat = menopausal status. 
 a = p< .05, b = p< .01, c = p >.10 (only listed for depression & MS); point-biserial for dichotomous x continuous; phi-correlation for dichotomous x 
dichotomous.
 Table 4:  Chi-square tests showing differences in psychiatric diagnoses (lifetime history or current) by 
major depression diagnosis (lifetime history or current) at baseline evaluation. 
 
 
Psychiatric Variable  n (%) within lifetime 
history / current major 
depression at visit 00 
n (%) within no lifetime 
history / no current major 
depression at visit 00 
Total N (%) 
    
Lifetime history / current 
drug abuse / dependence at 
visit 00 (n = 421) 
19 (12.6)* 16 (5.9) 35 (8.3%) 
    
Lifetime history / current 
alcohol abuse / dependence 
at visit 00 (n = 420) 
30 (20.0)** 24 (8.9) 54 (12.9%) 
    
Lifetime history / current 
anxiety disorder at visit 00 
(n = 421) 
49 (32.6)** 52 (19.2) 101 (24%) 
* Row Chi2 comparing depression to no depression; p < .05; ** Row Chi2 comparing depression to no 
depression; p < .01 
 
 
 
Table 5 presents the results of chi-square tests used to compare women with and without baseline 
depression (lifetime history / current) and women with and without the metabolic syndrome (baseline and 
cumulative through 05) on frequency of baseline antidepressant use (lifetime history / current).  Results 
showed that baseline antidepressant use was more common in women with the metabolic syndrome 
(baseline and cumulative at 05) as compared to women with no diagnosis of the metabolic syndrome, and 
in women with a lifetime history or current diagnosis of depression at baseline as compared to women 
with no depression (all p’s < .05).   
 
 
Table 5:  Lifetime history or current use of antidepressants at baseline by baseline depression and the 
cumulative index of the metabolic syndrome at visit 05 (ever from visit 00 - 05).  
 
 
Lifetime history 
/ current 
antidepressant 
use at visit 00 
MS at visit 00 1 Cumulative MS from 00-05 Lifetime history or current 
MD at visit 00 
 Absent 
N (%) 
Present 
N (%) 
Absent 
N (%) 
Present 
N (%) 
Absent 
N (%) 
Present 
N (%) 
       
No  291 (86.6%) 66 (77.6%) 176 (87.6%) 97 (78.9%) 256 (94.5%) 101 (67.3%) 
       
Yes 45 (13.4%) 19 (22.4%)* 25 (12.4%) 26 (21.1%)* 15 (5.5%) 49 (32.7%)**
Note: 1 MS = metabolic syndrome; MD = major depression; 
* Row Chi2 (comparing absent to present); p < .05; ** Row Chi2 (comparing absent to present); p < .01 
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 T-tests and chi-square tests were used to compare the demographic, psychiatric, and metabolic 
characteristics of participants with complete data for depression, the metabolic syndrome, and WC at all 
visits to women who were missing any of these variables at any visit.  As seen in Table 6, women with 
missing data had a lower mean age and education level; they were more likely to be Black and less likely 
to be premenopausal at baseline.  There were no differences in the prevalence of major depression or the 
metabolic syndrome at baseline; however, women with any missing data were more likely to have a 
current or past year diagnosis of major depression / subthreshold recurrence at follow-up visit 03 and 
more likely to have ever had the metabolic syndrome cumulatively from baseline through follow-up visit 
05 (all p’s < .05; see Table 6). 
 
 
 
3.2 MAIN ANALYSES – METABOLIC SYNDROME 
 
For simplicity, findings for Hypothesis 5 (e.g., race, menopausal status, diabetes, antidepressants, and 
other psychiatric diagnoses) and Hypothesis 6 (e.g., health behaviors) are incorporated into the 
description of the results for Hypotheses 2-4 and 7-8.  
 Hypothesis 1:  In comparison to subjects with no lifetime history or current diagnosis of major 
depression at baseline, subjects with major depression were expected to have greater frequency of the 
metabolic syndrome at baseline.  As expected, the percentage of subjects with major depression at 
baseline who had the metabolic syndrome at baseline (24.0%) was slightly greater than the percentage of 
subjects without major depression who had the metabolic syndrome at baseline (18.1%).  However, 
contrary to hypotheses, chi-square tests showed that this trend was not statistically significant (χ2 = 2.10, 
p > .10; see Table 7).   
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 Table 6:  Characteristics of participants missing data for depression, the metabolic syndrome, or waist 
circumference at any visit and participants with complete data for depression, the metabolic syndrome, 
and waist circumference at all visits. 
 
 
 N (%) 1 
 Not missing depression, MS, or 
WC at any visit 
Missing depression, MS, or WC 
at any visit 
   
Number of participants 227 194 
   
Age (years)* M = 45.86, SD = 2.49 M = 45.24, SD = 2.45 
   
Self-Identified Ethnicity: 
Black / African-American** 
63 (27.8%) 81 (41.8%) 
   
Education (years)* M = 15.22, SD = 2.17 M = 14.73, SD = 2.12 
   
Premenopausal at Visit 00** 133 (59.1%) 84 (43.5%) 
   
Major Depression or Subthreshold 
Recurrence 
  
Lifetime history / current at 
Visit 00  
79 (34.8%) 71 (36.6%) 
Visit 00 past year / current 21 (9.5%) 27 (14.0%) 
Visit 01  34 (15.0%) 18 (11.5%) 
Visit 02  35 (15.4%) 17 (10.7%) 
Visit 03* 21 (9.3%) 26 (17.3%) 
Visit 04 25 (11%) 19 (13.9%) 
Visit 05  25 (11%) 23 (18.3%) 
   
Metabolic Syndrome    
Visit 00 43 (18.9%) 42 (21.6%) 
Visit 01 45 (19.8%) 37 (26.8%) 
Visit 03 48 (21.1%) 24 (25.3%) 
Visit 05  45 (19.8%) 15 (25.4%) 
Ever from 00-05** 66 (29.1%) 57 (58.8%) 
Incident through 05** 23 (12.5%) 15 (27.3%) 
   
Waist Circumference (cm)   
Visit 00*  M = 86.45, SD = 15.00 M = 89.64, SD = 15.33 
Visit 01  M = 87.50, SD = 15.46 M = 90.55, SD = 15.58 
Visit 02*  M = 88.43, SD = 15.02 M = 92.20, SD = 15.88 
Visit 03 M = 89.16, SD = 15.77 M = 91.56, SD = 15.62 
Visit 04  M = 89.76, SD = 15.12 M = 91.48, SD = 14.99 
Visit 05  M = 89.09, SD = 15.66 M = 92.19, SD = 15.33 
HOMA-IR   
Visit 00 M = 2.76, SD = 4.39 M = 2.77, SD = 2.97 
Visit 01  M = 3.04, SD = 5.53 M = 2.81, SD = 3.06 
Visit 03  M = 3.10, SD = 5.76 M = 3.08. SD = 3.74 
Visit 05  M = 2.93, SD = 4.41 M = 3.44, SD = 5.47 
1 M = mean; SD = standard deviation; MS = metabolic syndrome; WC = waist circumference   
* T-tests (continuous) or Chi2 (categorical) comparing missing to non-missing; groups differ significantly at 
p<.05. 
** T-tests (continuous) or Chi2 (categorical) comparing missing to non-missing; groups differ significantly 
at p<.01. 
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Table 7:  Hypothesis 1: Baseline association between lifetime history or current major depression and the 
metabolic syndrome. 
 
 
 Lifetime History or Current Major Depression at Visit 00 
Metabolic Syndrome 
at 00 
Absent 
n (%) 
Present 
n (%) 
Chi2 * p-value 
     
Absent 222 (82.2) 114 (75.5)   
     
Present 49 (18.1) 36 (24.0)   
     
Total 271 150 2.10 .15 
* Chi2 comparing depression to no depression. 
 
 
 
Hypothesis 2a:  In comparison to women with no depression at baseline, women with baseline 
depression (lifetime history / current) were expected to have greater odds of having the metabolic 
syndrome cumulatively from baseline – visit 05 (Figure 3a).  As seen in Table 8, results of the univariate 
logistic regression model showed that women with major depression at baseline had 1.55 greater odds of 
having the metabolic syndrome at any point during the study than women with no baseline depression (p 
< .10).  The association between depression and the metabolic syndrome became slightly stronger and 
significant after adjusting for baseline age and race (OR = 1.62; p < .05); age and Black race were also 
associated with greater odds of having the metabolic syndrome at any point during the study (p’s < .10; 
see Table 8).  
Separate multivariate models were constructed with each planned covariate that was significantly 
associated with baseline depression (lifetime history / current) or the metabolic syndrome (baseline or 
cumulative 05) in univariate analyses, as well as those covariates which differed significantly between 
women with and without baseline depression.  Depression, age, and race were entered on step 1, 
followed by each of the covariates.  As seen in Table 8, baseline depression continued to predict 
significantly greater odds of having the metabolic syndrome cumulatively over the course of the study, 
after controlling for baseline menopausal status, physical activity, percent calories from fat, and diabetes 
diagnosis, although the association between depression and the metabolic syndrome became stronger 
when physical activity was added to the model.  There were no significant interactions between 
depression and any of these covariates (all p’s > .10; results not shown).     
 Table 8:  Logistic regressions showing the association of baseline major depression (lifetime history / current) predicting cumulative index of the 
metabolic syndrome at visit 05 (ever from 00 – 05). 
 
 
DV: Presence of MS ever from 00-05 1 
  
Variable 
 
OR (95% CI) 
 
p-value 
Univariate (n = 324)    
Step 1:    
 Depression 1.55 (0.98, 2.46) .064 
 
Age and Race  (n = 324  ) 
   
Step 1:    
 Depression 1.62 (1.01, 2.59) .046 
 Age 1.12 (1.02, 1.22) .020 
 Race (Black) 1.67 (1.02, 2.72) .040 
    
Menopausal Status    
Step 2:     
 Depression 1.63 (1.02, 2.62) .042 
 Age 1.12 (1.02, 1.22) .021 
 Race (Black) 1.66 (1.02, 2.71) .043 
 Menopausal status (early perimenopause) 1.12 (0.70, 1.79) .629 
 
Physical activity at visit 00 (n = 322 ) 
   
Step 2:    
 Depression 1.74 (1.07, 2.83) .026 
 Age 1.20 (1.02, 1.23) .019 
 Race 1.39 (0.84, 2.32) .201 
 Physical Activity (-) 0.76 (0.65, 0.88) <.0001 
 
% kcal fat at visit 00 (n = 324 ) 
   
Step 2:    
 Depression 1.62 (1.01, 2.59) .047 
 Age 1.11 (1.02, 1.22) .021 
 Race 1.61 (0.99, 2.64) .057 
 % kcal fat 1.03 (0.99, 1.06) .093 
1 DV = dependent variable; OR = odds ratio; CI = confidence interval 
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Table 8: (continued) 
 
DV: Presence of MS ever from 00-05 1 
  
Variable 
 
OR (95% CI) 
 
p-value 
History / current other psychiatric diagnosis at 
visit 00 (n = 323 ) 
   
Step 2:    
 Depression 1.53 (0.94, 2.48) .087 
 Age 1.12 (1.02, 1.23) .020 
 Race 1.59 (0.97, 2.61) .066 
 Alcohol use / abuse 1.75 (0.84, 3.65) .135 
 Drug use / abuse 1.03 (0.40, 2.69) .949 
 Any anxiety disorder (-) 0.89 (0.50, 1.58) .693 
 
Antidepressant use at visit 00 (n = 324 ) 
   
Step 2:    
 Depression 1.37 (0.83, 2.28) .219 
 Age 1.12 (1.02, 1.23) .018 
 Race 1.79 (1.09, 2.94) .022 
 Antidepressants  1.86 (0.96, 3.59) .067 
 
Diabetes at visit 00 (n = 322 ) 2 
   
Step 2:    
 Depression 1.75 (1.06, 2.88) .029 
 Age 1.11 (1.00, 1.22) .042 
 Race 1.55 (0.92, 2.62) .102 
 Diabetes 44.27 (5.84, 335.86) <.0001 
1 DV = dependent variable; OR = odds ratio; CI = confidence interval 
2 Results were similar if participants with baseline diagnosis of diabetes (n=25) were eliminated rather than controlled for. 
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The association between depression and the metabolic syndrome was reduced and became 
marginal after controlling for baseline psychiatric diagnoses (anxiety disorder, alcohol abuse / 
dependence, drug abuse / dependence; OR = 1.53; p < .10); however, none of the psychiatric diagnoses 
was a significant factor in the model (all p’s >.10; see Table 8).  Results were similar when three separate 
models were constructed with each psychiatric diagnosis at baseline entered separately on step 2, 
although none of the psychiatric diagnosis was a significant predictor of the metabolic syndrome (p > .10 
for each psychiatric diagnosis; results not shown), and depression remained a marginally significant or 
significant predictor of the metabolic syndrome in these models.   As seen in Table 8, the association 
between depression and the metabolic syndrome was no longer significant when baseline antidepressant 
use was entered on step 2 (p > .10); antidepressant use was associated with approximately twice the 
odds of having the metabolic syndrome at some point over the course of the study (p < .10).  There were 
no significant interactions between depression and any of these covariates (all p’s > .10; results not 
shown). 
Hypothesis 2b:  In women who were free of the metabolic syndrome at baseline, women with 
baseline depression (lifetime history / current) were expected to have greater odds of developing the 
metabolic syndrome over the course of the follow-up period (“cumulative index” of incident cases, visit 01 
– 05) as compared to women with no depression (Figure 3b).  As seen in Table 9, results of the univariate 
logistic regression model showed that women with depression had 1.66 greater odds of developing the 
metabolic syndrome by the end of the study, as compared to women with no baseline depression; 
however, this effect was not significant (p > .10).  Odds of developing the metabolic syndrome increased 
slightly after controlling for baseline age and race (OR = 1.74), although this effect was still not significant 
(p > .10; see Table 9).  Menopausal status was not associated with the metabolic syndrome and did not 
affect the association between depression and the metabolic syndrome (results not shown).  
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Table 9:  Logistic regressions showing the association of baseline major depression (lifetime history / current) predicting cumulative index of 
incident cases of the metabolic syndrome at visit 05 (ever from 01 – 05) in women who were free of the metabolic syndrome at baseline. 
 
 
DV: Incident MS ever from 01 - 05 in participants free of MS at 00 1, 2 
  
Variable 
 
OR (95% CI) 
 
p-value 
Univariate (n = 239)    
Step 1:    
 Depression 1.66 (.82, 3.35) .160 
    
Age and Race (n = 239)    
Step 1:    
 Depression 1.71 (.84, 3.48) .137 
 Age 1.08 (.94, 1.24) .265 
 Race 1.42 (.67, 3.00) .357 
    
Physical activity score at visit 00 (n = 238)    
Step 2:    
 Depression 1.77 (0.86, 3.63) .196 
 Age 1.09 (0.95, 1.25) .244 
 Race 1.09 (0.50, 2.40) .828 
 Physical activity 0.78 (0.62, 0.98) .030 
Note: 1 DV = dependent variable; OR = odds ratio; CI = confidence interval  
2 Results were similar if participants with baseline diagnosis of diabetes (n=25) were eliminated. 
 Hypothesis 3:  In women who were free of the metabolic syndrome at baseline, participants with 
baseline depression (lifetime history / current) were expected to have greater risk for developing the 
metabolic syndrome across the five-year follow-up compared to women with no baseline depression 
(Figure 4).  Among the 336 women who were free of the metabolic syndrome at baseline, a total of 38 
women (11.3%) developed the metabolic syndrome over the course of the study; 22 first met criteria at 
follow-up visit 01, 13 first met criteria at visit 03, and 3 first met criteria at visit 05.  The median follow-up 
length was 6 years with a range of 2 to 6 years.  Chi-square and t-tests were used to compare 
characteristics of the 85 women who had the metabolic syndrome at baseline to the remaining 336 
women who were used for the current analyses.  Results showed that women with the metabolic 
syndrome at baseline were older and had lower physical activity scores (p’s < .01), had greater percent 
caloric intake from fat (p < .05), and were more likely to report a lifetime history or current use of 
antidepressants at baseline (p < .05); there were no other significant group differences.    
Within the 336 participants used for the current analyses, chi-square and t-tests were used to 
compare characteristics of women who developed the metabolic syndrome to those who remained free of 
the metabolic syndrome.  Results showed that women who developed the metabolic syndrome had lower 
physical activity scores (p < .05) and were slightly more likely to be smokers (p = .09) at baseline; there 
were no other significant group differences.  
Results of the univariate and multivariate Cox models conducted to examine the association 
between baseline depression and risk for developing the metabolic syndrome are displayed in Table 10.  
Univariate results showed that women with depression were 60% more likely to develop the metabolic 
syndrome over the course of the follow-up visits than women with no baseline depression; however, 
although this trend was in the predicted direction, it was not statistically significant (p = 0.15).  Event-free 
Kaplan-Meier survival curves for women with and without a baseline diagnosis of depression are 
presented in Figure 9.  As demonstrated in Figure 9, survival curves for women with and without 
depression were proportional, and women with a baseline diagnosis of depression had a lower “event-
free survival rate” than women with no depression, indicating that women with baseline depression were 
less likely to remain free of the metabolic syndrome over the course of the study.  
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Figure 9: Event-free Kaplan-Meier survival curves for women with and without a lifetime history / current 
diagnosis of depression at baseline 
 
 
 
As seen in Table 10, results were similar after adding baseline age and race to the model, such that a 
lifetime history or current diagnosis of depression at baseline was associated with 66% greater risk of 
developing the metabolic syndrome over the course of the follow-up (p = .12), although this difference 
was not significant; older age at baseline was associated with marginally greater risk of developing the 
metabolic syndrome across follow-up (p < .10).  This model (depression, age, and race) was used as the 
“basic” model for all further analyses.  Baseline menopausal status (early perimenopause compared to 
premenopause) was not associated with risk for the metabolic syndrome (p > .10).  In the fully adjusted 
model controlling for age, race, antidepressant use, physical activity, percent caloric intake from fat, and 
psychiatric diagnoses, the risk associated with major depression decreased to 56% (p = .22); physical 
activity was the only significant covariate in this model (p < .05; see Table 10).  To make the relationship 
between physical activity and the metabolic syndrome more meaningful, a standardized score (z-score; 
mean of 0) was created for physical activity and the model was rerun with this standardized score.  
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 Results of this model showed that the risk for developing the metabolic syndrome decreased by 
approximately 30% with every one standard deviation increase in the physical activity score (see Table 
10).  To create the most parsimonious model, covariates which were not related to the metabolic 
syndrome at the p < .10 level in the fully adjusted model were removed.  In this final model, baseline 
physical activity remained a significant predictor of risk for the metabolic syndrome, and the risk 
associated with major depression was very similar to that in the “basic” model (p > .10; see Table 10).  
Hypothesis 4:  A lifetime history or current diagnosis of depression (major depression or 
subthreshold recurrence) at each visit (visits 00, 01, 03, and 05) was expected to be associated with 
greater odds of having the metabolic syndrome at each visit (visits 00, 01, 03, and 05; Figure 5a).  
Results of univariate and multivariate GEE models are presented in Table 11.  Contrary to our 
hypothesis, depression was not associated with greater odds of having the metabolic syndrome in 
univariate or multivariate models (p’s > .50).  Age was a marginally significant predictor of the metabolic 
syndrome, such that older age was associated with slightly greater odds of having the metabolic 
syndrome (p < .10); there was no significant interaction between age and depression (p > .10; results not 
shown).  Similar results were found when antidepressant use (baseline – visit 05) or menopausal status 
(visits 01-05), were added to the model (see Table 11).  In addition to age and race, diabetes status at 
each visit was also added to the multivariate model.  Although diabetes was associated with significantly 
greater odds of having the metabolic syndrome (OR = 8.02; 95% CI = 4.46, 14.42; p < .001), depression, 
age, and race were not significant factors in this model, and there was no interaction between depression 
and age (results not shown).  Similarly, results of analyses conducted with women who were free of 
diabetes at baseline did not differ from those reported with the full sample (results not shown). 
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 Table 10:  Cox proportional hazard model of the association between baseline major depression (lifetime 
history or current) and risk of developing the metabolic syndrome through visit 05. 
 
 
Model  
(n = 336) 
Predictor Variable Hazard Ratio 
(95% CI) 1,2 
p-value 
1 Lifetime history / current MD at visit 00 1.60 (0.85, 3.04) .150 
    
2 Lifetime history / current MD at visit 00 1.65 (0.87, 3.13) .130 
 Age at visit 00 1.11 (0.99, 1.26) .080 
    
3 Lifetime history / current MD at visit 00 1.66 (0.87, 3.15) .120 
 Age at visit 00 1.12 (0.99, 1.26) .078 
 Race (Black) 1.10 (0.56, 2.15) .784 
    
4 Lifetime history / current MD at visit 00 1.67 (0.88, 3.12) .120 
 Age at visit 00 1.11 (0.99, 1.26) .080 
 Race (Black) 1.09 (0.56, 2.14) .802 
 Menopausal status at visit 00 (early perimenopause) 0.81 (0.43, 1.54) .533 
    
5 Lifetime history / current MD at visit 00 1.56 (0.77, 3.20) .022 
 Age at visit 00 1.13 (0.99, 1.28) .065 
 Race (Black) 0.87 (0.42, 1.80) .699 
 Lifetime history / current antidepressant use at visit 00  1.31 (0.52, 3.28) .567 
 Physical activity score at visit 00 0.80 (0.65, 0.99) 
z-score = 0.69 
.036 
 Percent fat intake at visit 00 0.99 (0.95, 1.03) .679 
 Lifetime history / current anxiety disorder at visit 00 0.63 (0.27, 1.48) .286 
 Lifetime history / current alcohol at visit 00 1.50 (0.58, 3.87) .399 
 Lifetime history / current drug at visit 00 1.57 (0.53, 4.71) .418 
    
6 Lifetime history / current MD at visit 00 1.64 (0.87, 3.12) .129 
 Age at visit 00 1.13 (0.99, 1.27) .062 
 Race (Black) 0.88 (0.44, 1.77) .713 
 Physical activity score at visit 00 0.80 (0.65, 0.99) .036 
Note: 1 CI = confidence interval; MD = major depression 
2 Results were similar when sample was restricted to participants with no diabetes at baseline (n = 334). 
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 Table 11: Results of Generalized Estimating Equation (GEE) models showing the relationship between 
depression (at visits 00, 01, 03, and 05) and odds of having the metabolic syndrome (at visits 00, 01, 03, 
and 05) 1 
 
 
Model  
(n = 421) 
Predictor Variable Relative odds of 
having the MS (95% 
CI) 2 
p-value 
1 MDE or subthreshold recurrence  1.03 (0.82, 1.30) .790 
    
2 MDE or subthreshold recurrence  1.09 (0.85, 1.38) .500 
 Age  1.03 (0.99, 1.07) .062 
    
3 MDE or subthreshold recurrence  1.09 (0.85, 1.39) .497 
 Age  1.04 (0.99, 1.07) .056 
 Race (Black) 1.34 (.87, 2.07) .188 
    
4 MDE or subthreshold recurrence  1.08 (0.85, 1.38) .537 
 Age 1.05 (1.01, 1.10) .029 
 Race (Black) 1.36 (0.88, 2.09) .171 
 Menopausal status (compared to pre / 
early peri) 
  
 Late peri 0.71 (0.47, 1.06) .094 
 Post / Surgical 0.92 (0.67, 1.27) .613 
 Unknown due to HRT 0.84 (0.59, 1.19) .323 
    
5 MDE or subthreshold recurrence  1.11 (0.86, 1.44) .414 
 Age  1.03 (0.99, 1.07) .063 
 Race (Black) 1.36 (0.88, 2.10) .165 
 Antidepressant use 1.01 (0.71, 1.44) .945 
Note: 1 Depression, metabolic syndrome, age, menopausal status, and antidepressant use all treated as 
time-varying variables; 2 MS = metabolic syndrome; CI = confidence interval; MDE = major depressive 
episode; HRT = hormone replacement therapy 
 
 
 
Time-lag 
  A lifetime history or current diagnosis of depression at any point up to and including each visit 
(cumulative depression, lifetime and visits 00, 02, and 04) was expected to be associated with greater 
odds of having the metabolic syndrome at the following visit (visits 00, 01, 03, and 05), independent of 
concurrent age and race (Figure 5b).  Contrary to our hypothesis, the cumulative index of depression was 
not associated with significantly greater odds of having the metabolic syndrome at the following visit in 
univariate or multivariate models (p’s > .10; see Table 12).   
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 Table 12:  Results of Generalized Estimating Equation (GEE) time-lag models showing the relationship 
between a cumulative index of depression (presence of depression up through and including the current 
visit; lifetime, 00, 02, and 04) and odds of having the metabolic syndrome at the following visit (visits 00, 
01, 03, and 05) 1  
 
 
Model  
(n = 421 ) 
Predictor Variable Relative odds of having 
the MS at the next visit 
(95% CI) 2 
p-value 
1 Cumulative depression up through and 
including each visit  
1.15 (0.86, 1.55) .341 
    
2 Cumulative depression up through and 
including each visit  
1.10 (0.81, 1.50) .532 
 Age  1.02 (0.99, 1.06) .193 
    
3 Cumulative depression up through and 
including each visit  
1.11 (0.81, 1.51) .508 
 Age  1.02 (0.99, 1.06) .180 
 Race (Black) 1.35 (0.88, 2.09) .170 
    
4 Cumulative depression up through and 
including each visit  
1.12 (0.82, 1.52) .485 
 Age  1.04 (0.99, 1.09) .068 
 Race (Black) 1.37 (0.89, 2.11) .155 
 Menopausal status (compared to pre / 
early peri) 
  
 Late Peri 0.71 (0.47, 1.07) .098 
 Post / Surgical 0.90 (0.65, 1.27) .525 
 Unknown due to HRT 0.80 (0.56, 1.14) .223 
    
5 Cumulative depression up through and 
including each visit  
1.11 (0.81, 1.52) .513 
 Age  1.02 (0.99, 1.06) .214 
 Race (Black) 1.39 (0.90, 2.15) .138 
 Antidepressant use 1.06 (0.75, 1.50) .733 
Note: No significant interactions with race or age. 
1 Cumulative depression, metabolic syndrome, age, menopausal status, and antidepressant use all 
treated as time-varying variables; 2 MS = metabolic syndrome; CI = confidence interval; HRT = hormone 
replacement therapy 
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 3.2.1 Additional Analyses on the Metabolic Syndrome 
 
While results of analyses with depression and the metabolic syndrome were in a direction that is 
consistent with our hypotheses, there was often only a trend for statistical significance.  Based on 
preliminary findings that women who had taken antidepressants at any point up to and including the 
baseline visit were more likely to have the metabolic syndrome at baseline and cumulatively through 
follow-up visit 05 (compared to women who had never taken antidepressants), we explored the effect of 
adding women who had taken antidepressants but did not meet criteria for a major depressive episode (n 
=15 at baseline) to the “depression” group.  The term “depression” in this section will be used to refer to 
women with a lifetime history or current diagnosis of major depression, subthreshold recurrence, or 
antidepressant use.     
 As seen in Table 1 of Appendix B, with the addition of women who had taken antidepressants at 
baseline, the proportion of women with depression at baseline who met baseline criteria for the metabolic 
syndrome (24.2%) was marginally greater than the proportion of women who were free of depression and 
met criteria for the metabolic syndrome (17.7%; p < .10).  Similarly, results of the univariate logistic 
regression model showed that baseline depression was associated with 1.65 times greater odds of 
having the metabolic syndrome at some point over the course of the study (p < .05); this effect became 
stronger after controlling for baseline age and race (see Appendix B, Table 2).  In addition, in women who 
were free of the metabolic syndrome at baseline, the univariate logistic regression model showed that 
baseline depression was associated with 1.79 greater odds of developing the metabolic syndrome (p = 
.10); the odds ratio increased and became marginal after controlling for baseline age and race (p < .10; 
see Appendix B, Table 2). 
 Cox survival models, paralleling those outlined in Hypothesis 3, were constructed to explore the 
effect of the newly defined depression variable on risk of developing the metabolic syndrome over the 
course of the follow-up visits.  Consistent with the findings reported under Hypothesis 3, univariate and 
multivariate Cox models showed that depression was associated with increased odds of developing the 
metabolic syndrome over the course of the study.  Notably, as seen in Table 3 of Appendix B, the effect 
of depression was now stronger and marginally significant, such that women with baseline depression 
60 
 were 73% more likely to develop the metabolic syndrome over the course of the follow-up period than 
women with no depression at baseline (p = 0.09 for univariate model; results of multivariate models 
controlling for age and race, menopausal status, and physical activity were similar).   
 Results of GEE models conducted with the newly defined depression variable (coded as a time-
varying IV which included depression or antidepressant use at each visit) were no different from those 
with depression alone, such that depression / antidepressant across time use was not associated with 
odds of the metabolic syndrome across time in univariate (OR = 1.05; 95% CI = 0.83, 1.31; p > .50) or 
multivariate (OR = 1.09; 95% CI = 0.86, 1.38; p > .50, controlling for age at each visit and race) models 
(results not shown). 
 
 
 
3.3 SECONDARY ANALYSES - CENTRAL ADIPOSITY AND INSULIN RESISTANCE 
 
Hypothesis 7:  Baseline depression (lifetime history / current) was expected to be associated with 
greater central adiposity and insulin resistance at baseline and follow-up visit 05 (Figures 6 and 7).  
Results of univariate and multivariate GLMs testing for differences in mean WC (baseline and visit 05) 
between women with and without baseline depression are presented in Table 13.  Contrary to our 
hypothesis, there were no significant differences between depressed and non-depressed women in mean 
WC at baseline in univariate or multivariate models (p’s > .10).  Greater age and Black race were 
significant predictors of greater baseline WC (p’s < .05; see Table 13).  Although women with a baseline 
diagnosis of depression (lifetime history or current) had slightly greater mean WC at visit 05 than women 
with no depression at baseline, this difference was not statistically significant (p = .12; see Table 13).   
However, the difference between depressed and non-depressed women in mean WC at visit 05 became 
stronger and marginally significant after controlling for baseline age and race (p = .053).  Black race was 
also associated with significantly greater WC at visit 05 (p < .001).  Interestingly, the association between 
depression and WC at visit 05 was no longer significant when antidepressant use was entered into the 
model; there was no significant interaction between antidepressant use and depression.   
We explored whether the effect of depression on mean WC at baseline and visit 05 differed 
between Blacks and Whites by incorporating a race-by-depression interaction term into the above 
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 models.  The interaction was not significant in the model of baseline WC; however, the interaction 
showed a nonsignificant trend in the model of WC at visit 05 (p=.113), suggesting that the relationship 
between depression and WC may differ between Blacks and Whites.  Simple-effects analyses conducted 
with Blacks and Whites separately showed that, within Blacks, women with depression had significantly 
greater WC at follow-up visit 05 than women who were free of depression at baseline (p < .05).  However, 
depression was not a significant predictor of WC in Whites (see Table 13).  
Table 14 presents results of univariate and multivariate (controlling for baseline age and race) 
GLMs testing for differences in HOMA values (log-transformed; baseline and visit 05) between women 
with and without baseline depression.  Contrary to our hypothesis, there were no significant differences 
between depressed and non-depressed women in HOMA values at baseline or visit 05 (p’s > .50; 
univariate and multivariate models).  Findings did not change when participants who met criteria for 
diabetes at baseline or visit 05 were removed from the sample (results not shown).  Results showed that 
Blacks had significantly greater mean HOMA-IR values at baseline and visit 05, compared to Whites (p’s 
< .05); older age at baseline predicted significantly greater HOMA-IR values at visit 05 (p < .01). We 
explored whether the effect of depression on HOMA-IR values differed between Blacks and Whites by 
incorporating a race-by-depression interaction term into the baseline and visit 05 models; these 
interactions were not significant (p’s > .10; results not shown). 
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 Table 13:  Results of General Linear Model ANOVAs showing differences in mean waist circumference at 
baseline and visit 05 in women with and without baseline depression (lifetime history / current)  
 
 
Mean (SD) 1 
WC Assessment   F p-value 
WC at visit 00 2     
 No lifetime history / no 
current major depression 
at visit 00 
Lifetime history / 
current major 
depression at visit 00 
  
N 266 149   
     
Depression 87.48 (14.51) 88.64 (16.43) 0.56 .456 
     
Depression   0.99 .321 
Age at visit 00   6.40 .012 
Race (Black)   21.31 <.0001 
     
Depression   1.33 .250 
Age at visit 00   6.53 .011 
Race (Black)   20.95 <.0001 
Depression*Race   0.40 .529 
WC at visit 05 (N=269) 2     
 No lifetime history / no 
current major depression 
at visit 00 
Lifetime history / 
current major 
depression at visit 00 
  
N 199 114   
     
Depression 88.89 (14.85) 91.78 (16.76) 2.50 .115 
     
Depression   3.78 .053 
Age at visit 00   2.77 .097 
Race (Black)   20.19 <.0001
     
Depression   0.94 .333 
Age at visit 00   2.97 .086 
Race (Black)   22.60 <.0001
Antidepressant use 2   4.42 .036 
     
Depression   5.73 .017 
Age at visit 00   3.10 .079 
Race (Black)   22.81 <.0001
Depression*Race   2.53 0.113 
     
Blacks (n) 71 34   
Depression 92.73 (13.93) 99.94 (18.23) 4.97 .028 
Age at visit 00   0.02 .884 
     
Whites (n) 128 80   
Depression 86.76 (14.97) 88.32 (14.91) 0.57 .471 
Age at visit 00   3.95 .048 
Note: 1 SD = standard deviation; WC = waist circumference; 2 Lifetime history / current at visit 00, no 
significant interaction between antidepressants and race. 
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 Table 14:  Results of General Linear Model ANOVAs showing differences in mean HOMA-IR levels at 
baseline and visit 05 in women with and without baseline depression (lifetime history or current) 
 
 
Raw Mean (SD) 1 
HOMA-IR Assessment   F p-value 
 
HOMA-IR at 00 (N=412) 2 
    
 No lifetime history / 
no current major 
depression at visit 00 
Lifetime history / 
current major 
depression at visit 00 
  
     
N 264 148   
     
Depression 2.91 (4.46)  2.50 (2.14) 0.28 .600 
     
Depression   0.13 .715 
Age at visit 00   0.88 .350 
Race (Black)   9.18 .003 
 
HOMA-IR at 05 (N=269) 2 
    
 No lifetime history / 
no current major 
depression at visit 00 
Lifetime history / 
current major 
depression at visit 00 
  
     
N 176 93   
     
Depression 3.02 (4.87)  3.08 (4.26) 0.28 .598 
     
Depression   0.35 .553 
Age at visit 00   7.45 .007 
Race (Black)   5.52 .020 
Note: 1SD = Standard Deviation  
2 Analyses conducted with log-transformed HOMA values; means and standard deviations presented for 
raw scores. Values were transformed with sample that included participants with diabetes; results were 
similar if participants with diabetes were removed from analyses. 
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 Hypothesis 8:  A diagnosis of major depression or subthreshold recurrence (at each visit) was 
expected to be associated with higher WC (at each visit) across time (Figure 8a).  As shown in Table 15, 
results of GEE models showed that depression was associated with significantly lower WC in the 
univariate (p < .001) and multivariate model (p < .05; controlling for age at each visit and race).  Age and 
Black race were significant predictors of greater WC (p’s < .001); menopausal status was not a significant 
predictor when added to the model with age and race (p > .10).   
 All planned covariates which were significantly correlated with major depression or WC at 
baseline were entered into the multivariate models to examine their effect on the relationship between 
depression and WC.  As seen in Table 15, the inverse association between depression and WC remained 
significant in this fully adjusted model (p < .05), along with age (time-varying), Black race, antidepressant 
use (time-varying), and baseline physical activity (p’s < .05).  There was no significant depression-by-age 
interaction (p > .10; results not shown).  We explored whether the association between depression and 
WC varied by race or antidepressant use; neither interaction term was significant (p’s > .10, results not 
shown).  To create the most parsimonious model, analyses were conducted including only those 
covariates which were significant at the p < .10 level in the full model; results did not differ from the results 
of the full model (results not shown).  Four separate models were also constructed for each of the four 
significant covariates (activity (baseline), total calories (baseline), antidepressant use (time varying), and 
any anxiety disorder (time-varying)) added to the model with age, race, and depression.  The inverse 
association between depression and WC continued to be significant in each of these models (p’s < .05; 
results not shown).   
 Post-hoc analyses were used to explore potential explanations for the inverse association 
between depression and WC.  Although there was no significant interaction between depression and 
race, follow-up analyses were conducted with the sample stratified by race to explore whether the 
association between depression and WC across time varied between Blacks and Whites.  Results 
showed that the negative association was marginally significant in Whites, but not Blacks, suggesting that 
this inverse relationship may be particularly true for Whites (results not shown).  Results of analyses 
conducted with the sample stratified by baseline BMI suggested that the inverse association between 
depression and WC may be particularly salient in women with a “low” (BMI < 30) rather than “high” (> 30)  
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 Table 15:  Results of Generalized Estimating Equation (GEE) models showing the relationships between 
depression at each visit and waist circumference at each visit 1 
 
 
Model  
(n = 421) 
Predictor Variable Regression coefficient 
(95% CI) 2 
p-value 
 MDE or subthreshold recurrence -1.50 (-2.2, -0.84) <.001 
    
1 MDE or subthreshold recurrence -0.84 (-1.50, -0.18) .013 
 Age  0.51 (0.40, 0.62) <.001 
    
3 MDE or subthreshold recurrence -0.84 (-1.51, -0.17) .014 
 Age  0.51 (0.40, 0.62) <.001 
 Race (Black) 6.51 (3.57, 9.44) <.001 
    
4 MDE or subthreshold recurrence -0.85 (-1.52, -0.18) .013 
 Age  0.51 (0.38, 0.64) <.001 
 Race (Black) 6.53 (3.59, 9.47) <.001 
 Menopausal status (compared to pre / 
early peri) 
  
 Late peri 0.42 (-0.49, 1.34) .367 
 Post / Surgical -0.28 (-1.16, 0.58) .524 
 Unknown due to HRT 0.60 (-.022, 1.42) .150 
    
5 MDE or subthreshold recurrence -0.92 (-1.63, -0.21) .01 
 Age  0.50 (0.39, 0.61) <.001 
 Race (Black) 6.43 (3.48, 9.37) <.001 
 Antidepressant use 1.04 (0.02, 2.07) .046 
    
6 MDE or subthreshold recurrence -0.85 (-1.57, -0.12) .022 
 Age  0.48 (0.37, 0.60) <.001 
 Race (Black) 4.69 (1.66, 7.72) .002 
 Antidepressant use 1.06 (0.03, 2.09) .043 
 Smoker  -0.23 (-0.77, 0.31) .407 
 Physical activity level at visit 00 -1.64 (-2.48, -0.81) <.001 
 Total kcal at visit 00 0.002 (-0.00, 0.004) .056 
 Percent fat intake at visit 00 0.09 (-0.28, 0.46) .626 
 Percent carbohydrate intake at visit 00 -0.07 (-0.40, 0.25) .654 
 Any anxiety disorder  -0.78 (1.59, 0.03) .058 
 Alcohol abuse or dependence  1.36 (-2.07, 0.89) .435 
 Drug abuse or dependence  -0.02 (-1.99, 2.03) .981 
Note: 1 Depression, metabolic syndrome, age, menopausal status, antidepressant use, smoking status, 
and psychiatric disorders all treated as time-varying variables 
2 CI = confidence interval; MDE = major depressive episode; HRT = hormone replacement therapy 
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 BMI at baseline (results not shown).  Statistical and graphical examination of the data showed that the 
inverse association of depression with WC was not due to outliers, violations of normality, 
heteroscedasticity, nonlinearity, or missing data.2 
Time-lag 
 A lifetime history or current diagnosis of depression at any point up to and including each visit 
(cumulative depression; lifetime and visits 00-04) was expected to be associated with increased waist 
circumference at the following visit (visits 00-05), independent of concurrent age and race (Figure 8b).  As 
seen in Table 16, a diagnosis of depression at any point up through and including each visit was 
associated with increased WC at the following visit in univariate analyses (p < .05), although this effect 
was no longer significant after controlling for age (concurrent with WC) and race (p  > .10).  Age and 
Black race were significantly associated with greater WC across time (p’s < .001; see Table 16).  There 
was no effect of menopausal status (p > .10), and there was no significant interaction between depression 
and age or race (p’s > .10; results not shown). 
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 Table 16: Results of Generalized Estimating Equation (GEE) time-lag models showing the relationship 
between a cumulative index of depression at each visit (presence of depression up through and including 
the current visit; lifetime – visit 04) and waist circumference at the following visit (visits 00 – 05) 1  
 
 
Model  
(n = 421 ) 
Predictor Variable Regression coefficient 
(95% CI) 2 
p-value 
 
1 Cumulative depression up through and 
including each visit  
1.56 (0.50, 2.61) .004 
    
2 Cumulative depression up through and 
including each visit  
0.15 (-0.91, 1.21) .786 
 Age  0.52 (0.41, 0.63) <.001 
    
4 Cumulative depression up through and 
including each visit  
0.18 (-0.90, 1.25) .749 
 Age  0.53 (0.41, 0.64) <.001 
 Race (Black) 6.51 (3.57, 9.46) <.001 
    
5 Cumulative depression up through and 
including each visit  
0.14 (-0.93, 1.21) .799 
 Age  0.53 (0.39, 0.66) <.001 
 Race (Black) 6.53 (3.58, 9.48) <.001 
 Menopausal status (compared to pre / 
early peri) 
  
 Late peri 0.49 (-0.43, 1.41) .300 
 Post / Surgical -0.27 (-1.15, 0.62) .560 
 Unknown due to HRT 0.58 (-0.25, 1.41) .174 
Note: No significant interactions with race or age. 
1 Cumulative depression, waist circumference, age, and menopausal status all treated as time-varying 
variables 
2 CI = confidence interval; HRT = hormone replacement therapy 
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4. DISCUSSION 
 
 
The purpose of the current study was to investigate the relationship between clinical depression and the 
metabolic syndrome and its core components of central adiposity and insulin resistance in a community-
based sample of middle-aged women over a 6-year period.  This question was addressed in several 
ways.  First, we examined whether depression was associated with the metabolic syndrome, central 
adiposity, and insulin resistance at baseline (Figures 2 and 6) and across time (Figures 5a and 8a).  
Second, to help delineate the temporal sequence of the relationship between depression and the 
metabolic syndrome, we examined whether depression predicted increased risk of having or developing 
the metabolic syndrome in subsequent years of evaluation or over the course of the study (Figures 3a/b, 
4, and 5b) and whether depression similarly predicted elevated central adiposity and insulin resistance in 
subsequent years of evaluation (Figures 7 and 8b).  Finally, we explored whether these associations were 
independent of race, menopausal status, and potential confounding variables (e.g., diabetes, other 
psychiatric diagnoses, antidepressants), and we examined whether health behaviors accounted for the 
relationship between depression and the metabolic syndrome.   
 
 
4.1 SUMMARY OF FINDINGS 
 
Is depression concurrently associated with the metabolic syndrome, central adiposity, and insulin 
resistance at baseline and across time?   
Contrary to hypotheses, while the metabolic syndrome at baseline was more common among 
women with a lifetime history or current diagnosis of depression at baseline (Figure 2), this difference was 
not statistically significant.  Similarly, there was no significant association between depression at each 
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 visit and the metabolic syndrome at that same visit, across the course of the study (Figure 5a).  
Regarding the hypothesized association of baseline depression with WC and insulin resistance, results 
showed that depression was not associated with WC or insulin resistance at baseline.  Although we 
hypothesized that depression would be associated with greater WC across time (Figure 8a), results of 
longitudinal analyses showed that depression was inversely related to concurrent measures of waist 
circumference across time, and that this association was particularly salient in women with a BMI < 30 
kg/m2 and in Whites.   
Does depression predict greater risk of having or developing the metabolic syndrome, increased 
central adiposity, and insulin resistance over the course of time and during subsequent years?  
 As hypothesized, baseline depression predicted greater odds of having the metabolic syndrome 
over the course of the study (visit 00 – 05; Figure 3a).  However, in contrast to our hypotheses, 
depression at any point up through and including each year of observation (“cumulative” depression) was 
not associated with greater odds of having the metabolic syndrome during the following year of 
observation (Figure 5b).  In women who were free of the metabolic syndrome at baseline, we 
hypothesized that a lifetime history or current diagnosis of depression at baseline would predict increased 
risk of developing the metabolic syndrome over the course of the study (Figures 3b and 4).  Although 
results overall showed that depression at baseline was associated with approximately 60% greater risk of 
developing the metabolic syndrome, the effects were not statistically significant.    
Consistent with our hypothesis, baseline depression was associated with greater waist 
circumference at visit 05 (Figure 7), but this was marginally significant only after controlling for baseline 
age and race.  As predicted, the cumulative index of depression at each year of observation was 
associated with greater waist circumference at the following year of observation (Figure 8b); however this 
association was reduced to a nonsignificant trend upon controlling for age and race.  Contrary to 
hypotheses, baseline depression was not associated with insulin resistance at follow-up visit 05.   
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 Are the associations independent of race, menopausal status, diabetes, other psychiatric 
diagnoses, and use of antidepressants?  
 Descriptive Variables 
 As hypothesized, there were no race differences in the association between depression and the 
metabolic syndrome.  Although the interaction between race and depression was not significant in any 
model, results of exploratory analyses suggested that the positive association between baseline 
depression and waist circumference at the final visit (Figure 7) may be stronger in Blacks, whereas the 
inverse association between depression and concurrent measures of WC across time (Figure 8a) may be 
stronger in Whites.  Consistent with our expectations, the relationships of depression with the metabolic 
syndrome and central adiposity were independent of menopausal status and diabetes.  No hypotheses 
were made regarding the effects of age.  Nevertheless, in general, results showed that the associations of 
depression with the metabolic syndrome or waist circumference were strengthened upon controlling for 
age; however, age accounted for the positive association between the cumulative index of depression at 
each visit and waist circumference at the following visit. 
 Psychiatric Diagnoses and Antidepressant Use   
 The association between baseline depression and the metabolic syndrome at visit 05 was 
reduced when other baseline psychiatric diagnoses (e.g., anxiety disorders, alcohol abuse / dependence, 
drug abuse / dependence) were entered simultaneously into the model.  However, none of the other 
psychiatric disorders was a significant predictor of the metabolic syndrome in the full model or when 
entered alone into separate models with depression, age, and race.   
Lifetime history or current use of antidepressants at baseline was positively associated with the 
metabolic syndrome at baseline and cumulatively through visit 05, as well as elevated waist 
circumference at baseline and follow-up visit 05.  However, baseline antidepressants did not predict risk 
of developing the metabolic syndrome, and antidepressant use across time was not associated with the 
metabolic syndrome across time.  Interestingly, the associations of baseline depression with the 
cumulative index of the metabolic syndrome at visit 05 (Figure 3a) and waist circumference at visit 05 
(Figure 7), were no longer significant when baseline antidepressant use was entered into the model.  One 
possible interpretation of these findings is that antidepressants may account for the effect of baseline 
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 depression on the metabolic syndrome over time.  Nevertheless, if antidepressants were a mechanism by 
which depression influenced the metabolic syndrome, one would expect that antidepressants would 
predict increased risk of developing the metabolic syndrome.  Given that over 75% of the women who 
reported antidepressant use at baseline also met criteria for depression at baseline, it is plausible that 
antidepressant use may simply be a marker of depression, rather than a mechanism.  Consistent with this 
hypothesis, post-hoc analyses showed that the effect of baseline depression on the odds of having and 
developing the metabolic syndrome over time was strengthened when women who had taken 
antidepressants but did not meet diagnostic criteria for depression were added to the “depression” group.   
Although antidepressants were associated with greater waist circumference, they did not 
influence the inverse association between concurrent associations of depression and waist circumference 
across time (Figure 8a), and the addition of women who had taken antidepressants at baseline to the 
baseline depression group did not affect this association (results not shown).    
Do health behaviors reduce the association of depression with the metabolic syndrome, central 
adiposity, and insulin resistance? 
 Although physical activity was not associated with baseline depression, the effect of baseline 
depression on odds of developing the metabolic syndrome increased when baseline physical activity was 
entered into the model.  Post-hoc analyses, conducted with the sample stratified by “high” and “low” 
(median split) levels of physical activity, suggested that the effect of depression on odds of having or 
developing the metabolic syndrome over time was particularly salient in women with low levels of physical 
activity (results not shown).  Physical activity did not reduce or account for the associations between 
depression and waist circumference.   
Although there was an indication that caloric intake and percentage of calories from fat may have 
a small, adverse effect on the metabolic syndrome and central adiposity, the results overall suggest that 
dietary intake does not influence the association of depression with the metabolic syndrome or central 
adiposity.  While smoking tended to be associated with a lower waist circumference at baseline, it did not 
predict greater waist circumference and did not account for the associations between depression and 
waist circumference.   
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 4.1.1 Summary of Depression, the Metabolic Syndrome, and Central Adiposity 
 
 Overall, this study provides some preliminary evidence that clinical depression may be related to 
the metabolic syndrome and central adiposity in a community sample of Black and White middle-aged 
women undergoing the menopausal transition.  However, when considering these findings and comparing 
them with the current literature, it is important to note that the conclusions about the nature of these 
associations vary according to the type of analytic strategy and the outcome of interest.   
 Results of the longitudinal analyses which examined whether baseline depression predicted the 
odds of having the metabolic syndrome over the course of the study (Figure 3a), and whether baseline 
depression increased risk of developing the metabolic syndrome during follow-up (Figures 3b and 4), 
showed a trend indicating that clinical depression may adversely influence risk of the metabolic syndrome 
over time.  In contrast, the longitudinal analyses which examined the concurrent associations between a 
cumulative index of depression and the metabolic syndrome at the subsequent visit across time were not 
significant (Figure 5b), and the cross-sectional baseline analyses (Figure 2) and longitudinal analyses of 
the associations between repeated measurements of depression and the metabolic syndrome across 
time (Figure 5a) showed no significant effects.  One potential interpretation of these findings is that 
clinical depression may have a “long-term” adverse effect on risk of having or developing the metabolic 
syndrome at a later point in time, but depression and the metabolic syndrome may not be related in the 
“short-term” and they may not “track” together over time.   
Findings of the relationship between depression and central adiposity were similarly dependent 
upon the nature of the question and the statistical model.  Results of the analyses which examined 
whether baseline depression predicted increased waist circumference 5 years later (Figure 7) provide 
limited evidence that clinical depression may adversely influence waist circumference at a later point in 
time.  In addition, the longitudinal analyses of the relationship between the “cumulative index” of 
depression at each visit and waist circumference at the subsequent visit (Figure 8b) showed a 
nonsignificant trend in the hypothesized direction.  Together, these results suggest that depression may 
adversely affect the development of central adiposity, but this adverse effect may become more 
prominent with time.    
73 
 Cross-sectional analyses showed no relationship between depression and waist circumference at 
baseline (Figure 6); however, longitudinal models of the associations between repeated measurements of 
depression and waist circumference across time (Figure 8a) suggest that depression may be inversely 
associated with central adiposity across time.  This finding can be interpreted in two ways: first, 
depression may be related to lower concurrent measures of central adiposity across time; second, 
changes in depression (e.g., from not depressed to depressed) within women may be associated with 
decreases in central adiposity within that same woman.  Given that depressive episodes can be 
accompanied by changes in appetite and subsequent decreases in weight, it is possible that these results 
reflect this more “acute” effect of depression on weight, as opposed to the longer-term adverse effect of 
depression on the development of central adiposity.   
 
 
4.2 INTEGRATION WITH CURRENT LITERATURE 
 
As aforementioned, this is the first study to investigate the longitudinal relationship between clinical 
depression and the metabolic syndrome and analyze repeated measurements of depression, the 
metabolic syndrome, and central adiposity across time.  Thus, it is important to keep in mind that, while 
several studies have addressed questions which were similar to facets of this study, no study is directly 
comparable to the current investigation in its entirety.  Hence, these results should be interpreted as 
preliminary until future investigations are able to replicate the findings, particularly since many of the 
reported associations, while consistent with hypotheses, were marginally significant or nonsignificant 
trends.  
 
4.2.1 Metabolic Syndrome  
 
Most comparable to the current investigation, a report from the Healthy Women Study showed that 
women who had elevated baseline depressive symptom scores had significantly greater risk 
(approximately 30%) of developing the metabolic syndrome over the course of a 7-year follow-up period 
(Raikkonen et al., 2002).  This is consistent with our finding that a lifetime history or current diagnosis of 
74 
 depression at baseline was associated with significantly greater odds of having the metabolic syndrome 
over time (Figure 3a), and the nonsignificant finding that women with baseline depression were 
approximately 60% more likely to develop the metabolic syndrome over the course of the study.  Although 
the elevated risk in the current investigation was not statistically significant, the hazard ratio was 
approximately 25% higher than the hazard ratio reported by Raikkonen et al. (2002).  Thus, it is possible 
that the use of a categorical predictor (presence / absence of depression) and the relatively small number 
of women who developed the metabolic syndrome over the course of the study (n = 38) may have 
reduced the ability to detect significant differences in incident cases of the metabolic syndrome in the 
current study.  Hence, the risk associated with depression may have reached statistical significance in a 
sample with a greater incidence rate.  Additionally, in contrast to the women from the Healthy Women 
Study, the current sample of women was ethnically and sociodemographically diverse, it included women 
with other psychiatric and medical conditions (e.g., diabetes, hypertension), and it did not exclude people 
based on the use of psychotropic or other medications, making the current sample more representative of 
the general population.  Hence, it is possible that the effect of depression on the risk of developing the 
metabolic syndrome is stronger or more apparent in a relatively homogeneous sample of healthy women 
than it is in the general population. 
 The remaining studies of depression and the metabolic syndrome have been cross-sectional, 
limiting the ability to make direct comparisons with the current investigation.  In the only study of the 
association of clinical depression with the metabolic syndrome, Kinder et al. (2004) showed that a lifetime 
history of major depression was associated with greater odds of having the metabolic syndrome in young 
adult women.  In contrast, our results do not provide strong support for a cross-sectional association 
between clinical depression and the metabolic syndrome in middle-aged women (Figure 2), and they 
suggest that clinical depression and the metabolic syndrome may not be closely related across time 
(Figure 5a).  As mentioned above, one potential explanation for the differences in findings is that a 
lifetime history of depression may be more strongly associated with the metabolic syndrome in younger, 
healthy women as compared to the current sample of middle-aged women who may already have 
preclinical levels of disease (e.g., hypertension, obesity).  Consistent with this possibility, Kinder et al. 
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 showed that the relationship between depression and the metabolic syndrome was marginally stronger in 
women less than 30 years of age.   
Finally, cross-sectional data on depressive symptoms and the metabolic syndrome are mixed.    
In contrast to the current findings, previous studies have shown that elevated scores on continuous 
measures of depressive symptoms are associated with the metabolic syndrome in women (Raikkonen et 
al., 2002) and men (McCaffery et al., 2003).  However, results of a third study showed that women who 
met a clinically relevant cutoff for current depressive symptoms, relative to women who did not meet the 
cutoff, did not have greater odds of having the metabolic syndrome (Herva, Rasanen et al., 2006).  This 
raises the possibility that the variability in findings across studies may also be attributable to the 
operationalization of depression (e.g., continuous depressive symptoms, categorical depressive 
symptoms, clinical diagnosis of major depression), and that the association of depression with the 
metabolic syndrome may not be uniform across the spectrum of depressive symptomatology.  Thus, it is 
plausible that the “depressed” group in the current study was heterogeneous in terms of the severity, 
chronicity, and presentation of depression, and the variability within the “depressed” and the “non-
depressed” groups may have obscured potentially meaningful concurrent associations.  Given the nature 
of the calculations for the GEE models, this may also have implications for the longitudinal analysis of the 
relationships between depression and the metabolic syndrome across time (Figures 5a), as this analysis 
treated both depression and the metabolic syndrome as categorical time-varying factors, such that 
women were able to fluctuate between depression groups (i.e., “depressed” and “not depressed”) as well 
as metabolic syndrome groups (i.e., “metabolic syndrome present” and “metabolic syndrome absent”).  
Alternatively, the lack of an association between concurrent measures of depression and the metabolic 
syndrome across time in the current study may suggest that depressive episodes and the metabolic 
syndrome do not “track” together over time; that is, fluctuations in depression may not be associated with 
fluctuations in the metabolic syndrome.  Consistent with this possibility, Raikkonen et al. (2002) showed 
that individual changes in depressive symptoms from baseline to follow-up were not related to risk of 
developing the metabolic syndrome over time. 
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 4.2.2 Central Adiposity and Insulin Resistance      
 
Only four studies have used a longitudinal design to examine the association between depression   and 
central adiposity over time.  Consistent with the pattern of results in the current study (Figure 7), Nelson et 
al. (1999) found that elevated baseline scores on a continuous measure of depressive symptoms 
predicted significantly greater mean WHR 5-7 years later in middle-aged White women, suggesting that 
depression may predict greater subsequent central adiposity over an extended period of time.  However, 
the only longitudinal investigation of clinical depression and central adiposity  showed no differences 
between patients with current major depression and healthy controls in the amount of VAT at baseline or 
one year later (Weber-Hamann et al., 2006).  Interestingly, results of analyses conducted with the 
patients stratified by baseline levels of free cortisol showed that “normocortisolemic” patients, but not 
“hypercortisolemic” patients, had a marginally greater percent increase in VAT, although there were no 
differences between depressed patients in general and controls.   
The remaining longitudinal reports of depression and central adiposity examined changes in 
depressive symptoms and central adiposity over time; these analyses are most comparable to the current 
longitudinal model of the associations between time-varying measures of depression and waist 
circumference at each visit (Figure 8a).  Results of the first study, conducted with middle-aged White 
diabetic men and women, showed that changes in depressive symptoms from baseline to the 2-year 
follow-up were positively associated with changes in WHR (Lloyd et al., 1996).  On the contrary, in 
another report from the Healthy Women Study, Raikkonen, Matthews, & Kuller (1999) showed no 
association between changes in depressive symptoms and changes in WC across an 8-year follow-up 
(“within-subject” effect); however, women with greater overall WC across time, relative to women with 
smaller overall WC, reported more symptoms of depression across the follow-up period (“between-
subjects” effect).  These results are in contrast to the findings of the current study, which showed an 
inverse association between depression and waist circumference across time (Figure 8a).  Together, 
results of the longitudinal and cross-sectional studies, along with the results of the current investigation, 
suggest several potential explanations for the variation in findings.  More specifically, it is possible that the 
“short-term” and “longer-term” effects of depression on central adiposity differ, or that depression may 
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 influence subsequent changes in central adiposity over time, but this effect may not be apparent when 
one only examines absolute levels.  Finally, the previously described heterogeneity in depression (e.g., 
differences in depression presentation or differences in physiological aberrations) may also affect the 
association between depression and central adiposity.   
To explore the possibility that variability within the depression group may influence the overall 
associations between depression and waist circumference, a “chronicity” variable was created based on 
the number of depressive episodes from lifetime through visit 05 (0 = no episodes, 1 = a single episode, 2 
= more than 1 episode), and univariate GLM was used to compare the mean waist circumference at visit 
05 between these three groups.  Results showed that women with more than one depressive episode had 
significantly greater mean waist circumference than women with one or no depressive episodes (results 
not shown).  To further explore the variability in waist circumference within the “depressed” group, 
another variable was created based on the total number of episodes from lifetime – visit 05 (range 0-6), 
and univariate GLM was used to compare the mean waist circumference at visit 05 between these seven 
groups.  Although the main effect of the depression group was not significant, examination of group 
means showed that women with 3 and 5 depressive episodes had the greatest mean waist circumference 
at visit 05, while women with 6 depressive episodes actually had the lowest mean waist circumference at 
visit 05, suggesting that the relationship between the number of depressive episodes and waist 
circumference may not be linear in this sample (see Appendix C, Table 1); however, this should be 
interpreted with caution as the main effect was not significant.  Nevertheless, the considerable variability 
in mean waist circumference among women who would have fallen into the “depression” category may be 
another potential explanation for the inverse association between depression and waist circumference 
across time.   
Data from most cross-sectional investigations of clinically depressed young adults suggest that 
individuals with depression have greater levels of central or visceral adiposity than healthy controls 
(Eskandari et al., 2005; Kahl et al., 2005; Miller et al., 2003; Thakore et al., 1997), and elevated scores on 
continuous measures of depressive symptoms are associated with greater central adiposity in women 
and men (Ahlberg et al., 2002; Haukkala & Uutela, 2000; Katz et al., 2000; Lee et al., 2005; Petrlova et 
al., 2004; Wing et al., 1991), although null findings have been reported (Cota et al., 2001; Hach et al., 
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 2006; Herva, Laitinen et al., 2006; Marniemi et al., 2002).  Notably, although Weber-Hamann (2002) 
showed no significant differences between depressed patients overall and controls in mean levels of VAT, 
“hypercortisolemic” depressed patients had significantly greater levels of VAT than “normocortisolemic” 
patients but not controls, and “normocortisolemic” patients had significantly lower levels of VAT than 
controls.  In concert with the previously reported findings of Weber-Hamann (2006), these results 
highlight differences in HPA functioning among depressed patients and suggest that these physiological 
differences may influence the relationship of depression with the metabolic syndrome and central 
adiposity.   
Finally, previous cross-sectional research on depression and various proxies for insulin 
resistance or glucose intolerance has shown that clinical samples of depressed patients exhibit more 
metabolic impairment than healthy and psychiatric controls, and scores on continuous measures of 
depressive symptoms are associated with indicators of impaired glucose tolerance in White men (Ahlberg 
et al., 2002; Raikkonen et al., 1994) but not women (Huerta et al., 1995).  Results of cross-sectional 
studies of more direct measures of insulin resistance are mixed.  While one study demonstrated an 
association with depressive symptoms in young adult men (Timonen et al., 2006), another found an 
association in young adult women but not men (Suarez, 2006).  The only study of clinical depression 
showed that young women with comorbid major depression and borderline personality disorder, but not 
women with major depression alone, had more insulin resistance than healthy controls (Kahl et al., 2005).  
Finally, the only longitudinal investigation of depression and insulin resistance showed that baseline 
levels of depressive symptoms predicted greater HOMA-IR values at baseline; however, baseline 
depressive symptoms were not independently associated with changes in HOMA-IR values across time 
(Everson-Rose et al., 2004).   Although the literature provides mixed evidence for an association of 
depression with insulin resistance, the current investigation did not show an association between clinical 
depression and insulin resistance at baseline or over time in this sample.  Post-hoc analyses showed that 
this null finding was not due to baseline antidepressant use, baseline BMI, or baseline WC (results not 
shown).  As previously discussed, differences across studies may be attributable to differences in the 
measurement of depression and insulin resistance, sample demographics, and variability in depression 
as a construct.   
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 4.2.3 Health Behaviors 
 
There is some evidence to suggest that the metabolic syndrome is associated with unhealthy behaviors 
(Park et al., 2003), and that lifestyle behaviors may link psychological characteristics and components of 
the metabolic syndrome (Everson-Rose et al., 2004; Scherwitz et al., 1992).  Consistent with previous 
data (Raikkonen, Matthews, & Kuller, 1999), physical activity in this study did not account for the 
association between depression and waist circumference.  However, there was some indication that the 
effect of depression on the development of the metabolic syndrome was particularly strong in women with 
low baseline levels of physical activity.  It is plausible that physical activity may protect against the effect 
of depression on the metabolic syndrome or, alternatively, that low levels of physical activity may be a 
marker of more severe depression or metabolic dysregulation.  Consistent with previous research 
showing that smoking does not influence the association between depressive symptoms and central 
adiposity (Lee et al., 2005; Nelson et al., 1999; Raikkonen, Matthews, & Kuller, 1999), our results suggest 
that, while smoking may be associated with a lower waist circumference at baseline, it does influence the 
association of depression with central adiposity.  Together, these findings suggest that physical activity 
and, to a lesser extent, dietary intake, may affect the development of the metabolic syndrome and central 
adiposity.  However, they provide little support for lifestyle factors as a link between depression and the 
metabolic syndrome or its components in middle-aged women. 
 
 
 
4.3 SUMMARY OF STUDY STRENGTHS AND LIMITATIONS  
 
 
As highlighted throughout this paper, this study has several significant strengths.  Most importantly, it is 
the first investigation to longitudinally examine the relationship between a clinical diagnosis of depression 
and the metabolic syndrome across time.  In addition, this is the first study to examine the development of 
the metabolic syndrome over time as a function of baseline depression, to explore whether depression 
increases risk of developing the metabolic syndrome over time, and to investigate repeated 
measurements of depression, the metabolic syndrome, and central adiposity across time.  Moreover, this 
is the first study to examine the effects of health behaviors on the longitudinal association between clinical 
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 depression and the metabolic syndrome and investigate whether relationships between depression and 
the metabolic syndrome or central adiposity are independent of other psychiatric diagnoses.  Another 
strength of the current study is the use of a community-based, representative sample of middle-aged 
Black and White women undergoing the menopausal transition.  Few studies have investigated the 
association of depression with the metabolic syndrome or central adiposity in middle-aged women, 
despite evidence to suggest that risk of developing the metabolic syndrome and elevated central 
adiposity increases with age and may become particularly salient as women move through the 
menopausal transition (Carr et al., 2004).   
Nevertheless, this study has some notable limitations.  First, although the use of a diverse, 
community-based sample of middle-aged women increases the generalizability of the current findings, a 
potential disadvantage of this sample is that there are many variables which could influence the 
relationships of interest.  While an attempt was made to control for the potential “noise” of other factors, it 
is plausible that the heterogeneity within the sample as a whole may have obscured or altered 
associations of depression with the metabolic syndrome, central adiposity, and insulin resistance.  In 
addition, the age and gender of the current sample limits the application of the findings to men and 
younger populations.  A second limitation of the current investigation is that relatively few women 
developed the metabolic syndrome over the course of the study, possibly reducing the power to detect 
potentially significant effects of depression on the risk of developing the metabolic syndrome.  Similarly, 
while it is important to examine major depression as a clinical diagnosis, the use of a dichotomous 
predictor may have less statistical power to detect significant associations than continuous or ordinal 
variables, particularly if there is a dose-response or non-linear association.  As previously discussed, the 
heterogeneity among individuals diagnosed with depression (e.g., differences in number of episodes, 
types of symptoms, duration of episodes) may have obscured associations between depression, the 
metabolic syndrome, and central adiposity, particularly if the associations vary between these 
characteristics.  The use of a dichotomous indicator of depression, particularly as a time-varying predictor, 
may not have captured this potentially informative diversity.  Finally, the likelihood of committing a Type I 
error across all models may have increased as a function of the number of statistical tests performed. 
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 4.4 BIOLOGICAL PLAUSIBILITY 
 
As presented in Figure 1, the primary candidates for mediating biological pathways are dysregulation of 
the hypothalamic pituitary adrenal (HPA) axis and the sympathetic adrenal medullary (SAM) system, 
although there is also some preliminary evidence for a role of aberrant serotonergic functioning.  The 
HPA axis is implicated in the development and exacerbation of abdominal, visceral fat deposition and the 
metabolic syndrome through a variety of pathways (Surwit et al., 2002), and individuals with excess 
central or visceral adiposity exhibit HPA hypersensitivity and dysregulation (Philip & Facchini, 1995), 
frequently elevated levels of cortisol (Tanaka et al., 2004), and failure to habituate cortisol responses to 
stress (Miller, T. Q. et al., 1996).  Numerous studies have found indications of HPA hyperactivity in 
depressed patients (for review, see Park et al., 2003), and the behavioral symptoms of acute episodes of 
depression, including psychomotor alterations and decreased appetite, are purported to reflect elevated 
levels of corticotrophin-releasing hormone (CRH) (Gold & Chrousos, 1999; Gold & Chrousos, 2002).  
Interestingly, recent studies have highlighted the variability in HPA functioning among depressed patients, 
particularly between patients presenting with “melancholic” or “atypical” symptoms (Gold & Chrousos, 
1999; Gold & Chrousos, 2002), suggesting that the presentation of HPA “dysregulation” may differ among 
patients with major depression.  This is consistent with the findings of Weber-Hamann et al. (2002; 2006) 
and the hypothesis that variability within the depressed and non-depressed groups in the current study, 
perhaps in the associated HPA dysregulation, may have affected the associations between depression 
and waist circumference across time (Figures 8a & 8b).  In addition, there is some evidence that HPA 
alterations may not completely improve upon recovery from a depressive episode (Bhagwagar, Hafizi, & 
Cowen, 2003), and the remaining dysregulation may be a marker of or a risk factor for relapse (Appelhof 
et al., 2006). In the longer term, this HPA overactivity may contribute to increased central fat distribution 
and the development of the metabolic syndrome (Bjorntorp & Rosmond, 1999, 2000a, 2000b).  Thus, it is 
plausible that the inverse association between depression and central adiposity in the current 
investigation reflects the “acute” effects of HPA dysregulation, whereas the trend for an effect of baseline 
depression on greater central adiposity over time may reflect the more “long-term” effect of this 
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 dysregulation.  Alternatively, it is possible that certain types or characteristics of depression have more 
aberrant HPA functioning than others.   
Activation of the SAM system is also known to affect visceral fat deposition.  Catecholamines 
stimulate lipolysis and free fatty acid (FFA) mobilization, particularly in visceral fat cells (Roux, Jacobs, & 
Kiefe, 2002), reflected, for example, in the increased urinary catecholamine metabolite excretion exhibited 
by individuals with high central adiposity (Rebuffe-Scrive, Walsh, McEwen, & Rodin, 1992).  Given the 
evidence for autonomic dysregulation in depression (Carney, Freedland, & Veith, 2005), it is plausible 
that SAM activity may be a mechanism linking psychological factors with the metabolic syndrome.  
Finally, there is preliminary evidence to suggest that the metabolic syndrome and central adiposity may 
be associated with altered serotonergic functioning (Muldoon, et al., 2006; Muldoon et al., 2004; 
Rosmond, Bouchard, & Bjorntorp, 2002).  Aberrations such as decreased CSF concentrations of 
serotonin metabolites, decreased serotonin uptake and transporter binding, blunted neuroendocrine 
responses to serotonergic stimuli, and alterations in the density of serotonin receptors have all been 
demonstrated in individuals with depression, and alterations may remain even upon recovery from acute 
depressive episodes (for reviews, see Mann, 1999; Owens & Nemeroff, 1994; Stockmeier, 2003).  
 
  
 
4.5 STUDY IMPLICATIONS AND FUTURE DIRECTIONS 
 
 
The findings of the current investigation provide preliminary support for clinical depression as a predictor 
of increased risk for the metabolic syndrome.  Namely, the results of this study provide some preliminary 
evidence that women with a lifetime history or current diagnosis of major depression may be at greater 
risk of having and developing the metabolic syndrome over time (Figures 3 and 4).  In contrast, the 
results suggest that major depression overall may not be concurrently related to the metabolic syndrome 
and that depression “status” and the metabolic syndrome may not “track” together over time (Figures 2 & 
5).  This raises the possibility that there may be underlying physiological ramifications of depression 
which, over time, adversely affect metabolic processes and increase risk of developing the metabolic 
syndrome.  However, given the relatively small number of women who developed the metabolic 
syndrome over the course of the investigation, more research is needed to replicate these findings before 
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 drawing any definitive conclusions.  Importantly, the current findings suggest that cross-sectional studies 
of depression and the metabolic syndrome may not necessarily capture the “true” relationship between 
these variables, highlighting the need for future prospective investigations of the relationship between 
clinical depression and the metabolic syndrome.   
 Similarly, the current findings suggest that concurrent and longitudinal associations of clinical 
depression with central adiposity may differ.  More specifically, depressive episodes may be concurrently 
associated with lower waist circumference across time (Figure 8a), possibly reflecting a reduction in 
appetite and subsequent weight loss.  However, depression may adversely affect the development of 
central adiposity at a later point in time (Figures 7), consistent with the long-term effects of chronic HPA 
dysregulation or serotonergic dysfunction on body fat distribution.  Nevertheless, it is possible that these 
findings reflect differences among women in the individual associations between depression and waist 
circumference across time.  Although these findings should be considered preliminary, they underscore 
the potential importance of distinguishing short-term or concurrent associations between depression and 
central adiposity from prospective relationships. 
 This study also raises the possibility that the relationship between depression, the metabolic 
syndrome, and central adiposity may not be uniform among individuals with depression.  This presents 
important questions about our conceptualization of depression and its association with the metabolic 
syndrome which may have implications for integrating results from studies of depressive symptoms with 
investigations of major depression.  While these questions are beyond the scope of this study, future 
research could address these questions in several ways.  For example, studies could examine the effect 
of the chronicity of depression on the metabolic syndrome by comparing groups according to the number 
of depressive episodes or the total amount of time that an individual spends in a depressive episode, with 
the aim of capturing the effect of long-term exposure to clinical depression.  Alternatively, future studies 
could also examine individual trajectories among patients with depression to underscore the effect of 
changes in depression on individual changes in the parameters of the metabolic syndrome.  Another 
avenue for future research is to examine whether there are differences between depressive subtypes 
(e.g., melancholia, atypical depression) or levels of “severity” (e.g., major, subthreshold), and whether 
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 there are differences between individuals who meet diagnostic criteria for a depressive disorder and 
those who endorse depressive symptoms.   
 Results of the current study suggest that diet, physical activity, and smoking may not directly link 
clinical depression with risk of the metabolic syndrome, although future studies are needed to confirm this 
possibility.  Nonetheless, the question of how depression is related to the metabolic syndrome remains.  
In particular, this study did not examine whether the physiological aberrations presented on the left side of 
Figure 1 (e.g., hypothalamic, sympathetic, or serotonergic dysregulation) are pathways by which 
depression may affect risk for the metabolic syndrome.  Thus, future investigations should incorporate 
indicators of plausible biological mediators as well as health behaviors, and examine whether there are 
independent pathways or whether there is an underlying transactional process between health behaviors 
and physiological dysregulation.  Future research may also aim to explore whether common genetic 
factors or other common vulnerabilities (e.g., early traumatic experiences) link depression with the 
metabolic syndrome.   
Given the effect of antidepressant use on the association of depression with the metabolic 
syndrome and central adiposity in the current investigation, future investigations of the effect of 
antidepressant treatment on the association of depression with the metabolic syndrome and central 
adiposity are warranted.  More specifically, future studies should explore whether antidepressants are a 
pathway linking depression with the metabolic syndrome, a moderator of this association, or simply a 
marker depression (and possibly its severity or chronicity).  While there is some evidence to suggest that 
treatment with serotonergic agents decreases visceral fat deposition (Van Gal, Wauters, Peiffer, & De 
Leeuw, 1998), the data are not entirely consistent (Ljung et al., 2001).  Available literature suggests that 
the effect of antidepressants on body weight and appetite is dependent upon the type of antidepressant 
as well as the duration of antidepressant use, such that some antidepressants appear to be associated 
with weight gain, while others are associated with weight loss or no change in weight (for review, see 
Zimmerman, Kraus, Himmerich, Schuld, & Pollmacher, 2003).  Unfortunately, the current study did not 
have complete data on the specific types of antidepressants used at each visit, precluding a more 
detailed investigation of the effect of antidepressants on the associations between depression, the 
metabolic syndrome, and central adiposity.   
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 This study also highlights the importance of examining these questions in samples of men and 
women who are representative of the general population.  While the current study is a step toward a 
better understanding of the relationship between clinical depression and the metabolic syndrome in 
women, future studies are needed replicate these findings in diverse samples of women and men.  In 
addition, given the fairly high prevalence of precursors of the metabolic syndrome in children and 
adolescents (Goodman, Daniels, Morrison, Huang, & Dolan, 2004), investigations of the potential effect of 
depression in younger populations are warranted.   
If future research does establish a prospective link between depression and the metabolic 
syndrome, the next step is to experimentally test the hypothesis that depression is causally related to the 
metabolic syndrome.  One potential avenue for future work is to develop a trial of psychological 
interventions for depression (e.g. cognitive-behavioral therapy, interpersonal therapy) and follow its 
effects on the development, exacerbation, or remediation of the metabolic syndrome.  Alternatively, trials 
that intervene on the metabolic parameters (e.g. decreasing visceral adiposity through surgery, treating 
insulin resistance with pharmacotherapy, altering body fat distribution with lifestyle interventions) could be 
used to evaluate their effect on depression.  Only through these experimental manipulations will we be 
able to elucidate the true nature of the relationship between depression and the metabolic syndrome.   
Implications of this research extend beyond improving our understanding of the development of 
the metabolic syndrome itself.  Depression has long been recognized as significant risk factors for 
disease, including coronary heart disease and Type 2 diabetes (Musselman et al., 2003), and it may be 
associated with increased risk for these diseases in part through its association with the development of 
the metabolic syndrome.  However, no study to date has examined this hypothesis, highlighting the need 
for future investigations of the metabolic syndrome as a pathway linking depression with disease.  
Nevertheless, these findings suggest that a better understanding of the relationship between depression 
and the metabolic syndrome may provide a unique opportunity for the prevention and treatment of some 
of the major causes of morbidity and mortality.   
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 4.6 CONCLUSIONS 
 
 
Available literature on depression and the metabolic syndrome suggests that depression may be 
associated with increased central adiposity, insulin resistance, and the metabolic syndrome.  While cross-
sectional data suggest that depression, particularly depressive symptoms, is associated with increased 
central adiposity and insulin resistance, longitudinal data are less consistent.  The few studies of the 
metabolic syndrome in its entirety suggest that a history of major depression is cross-sectionally 
associated with presence of the metabolic syndrome, and depressive symptoms predict increased risk for 
developing the metabolic syndrome over time, although no study to date has prospectively examined the 
relationship between clinical depression and the metabolic syndrome.  Hence, the purpose of the current 
study was to investigate the relationship between clinical depression and the metabolic syndrome and its 
core components of central adiposity and insulin resistance in a community-based sample of middle-aged 
women over a 6-year period.   
Overall, this study provides some preliminary evidence that clinical depression may be related to 
the metabolic syndrome and central adiposity in Black and White women undergoing the menopausal 
transition.  More specifically, the current findings indicate that women with a lifetime history or current 
diagnosis of major depression may be at greater risk of having and developing the metabolic syndrome 
over time.  However, the results suggest that major depression overall may not be concurrently related to 
the metabolic syndrome and that depression “status” and the metabolic syndrome may not “track” 
together over time.  Given the relatively small number of women who developed the metabolic syndrome 
over the course of the investigation, more research is needed to replicate these findings before drawing 
any definitive conclusions.  Findings of the relationship between depression and central adiposity were 
similarly dependent upon the nature of the question and the statistical model.  Results showed that 
clinical depression may adversely influence the development of central adiposity at a later point in time, 
but findings suggest that depression may be inversely associated with concurrent measures of central 
adiposity across time.  It is possible that these findings reflect differences in the “short-term” and “long-
term” effect of clinical depression on central adiposity. The current study found no support for an 
association between clinical depression and insulin resistance in middle-aged women.  Importantly, the 
current findings, while preliminary, suggest that cross-sectional studies of depression and the metabolic 
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 syndrome may not necessarily capture the “true” relationship between these variables, highlighting the 
need for future prospective investigations of the relationship between clinical depression, the metabolic 
syndrome, and central adiposity.  In sum, the current study provides preliminary evidence for they 
hypothesis that major depression may be associated with risk of having the metabolic syndrome and 
increased central adiposity, suggesting that future investigations of the relationship between clinical 
depression and the metabolic syndrome are warranted.   
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 APPENDIX A.  DEPRESSION DEFINED AS MAJOR DEPRESSION, MINOR DEPRESSION, OR 
DYSTHYMIA  
 
 
 
Table A1: Characteristics of participants with a lifetime history or current major depressive episode at 
baseline, lifetime history or current minor depressive episode or dysthymia at baseline, and no lifetime 
history or current depression at baseline  
 
 
 No lifetime history / no 
current depression at 
visit 00 
n (%) 
Lifetime history / 
current minor 
depression or 
dysthymia visit 00   
n (%) 
Lifetime history / 
current major 
depression at visit 00 
n (%) 
    
Number of participants 209 62 150 
    
Major Depressive Episode    
Visit 01 (n = 384) 6 (3.1%) 3 (5.5%) 43 (31.6%) 
Visit 02 (n = 386) 7 (3.6%) 4 (7.3%) 41 (29.7%) 
Visit 03 (n = 377) 8 (4.3%) 4 (7.5%) 35 (25.5%) 
Visit 04 (n = 364) 4 (2.2%) 2 (3.9%) 38 (28.6%) 
Visit 05 (n = 353) 6 (3.4%) 4 (8.5%) 38 (29.2%) 
    
Metabolic Syndrome (MS)    
Visit 00 37 (17.7%) 12 (19.4%) 36 (24.0%) 
Visit 01 36 (19.5%) 10 (19.2%) 36 (28.1%) 
Visit 03 33 (20.1%) 7 (17.9%) 32 (26.9%) 
Visit 05 30 (20.5%) 5 (13.2%) 25 (24.5%) 
Cumulative MS 
(00-05) 
54 (33.5%) 16 (36.4%) 53 (44.5%) 
Incident MS (00-
05) 
17 (13.7%) 4 (12.5%) 17 (20.5%) 
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Table A2: Chi-square analyses showing baseline association between lifetime history or current diagnosis 
of any depression (redefined) and the metabolic syndrome 
 
  
 Lifetime History or Current Major Depression, Minor Depression, or Dysthymia at 
visit 00 
Metabolic 
Syndrome at visit 00 
Absent 
n (%) 
Present 
n (%) 
Chi2 * p-value 
     
Absent 172 (82.3) 164 (77.4)   
     
Present 37 (17.7) 48 (22.6)   
     
Total 209 212 1.60 .21 
* Chi2 comparing depression to no depression 
 
 
 
 Table A3:  Logistic regressions showing the association of lifetime history or current diagnosis of any depression predicting cumulative index of the 
metabolic syndrome at visit 05 (ever from 00 – 05) 
 
DV: Presence of the metabolic syndrome ever from 00 – 05 1 
  
Variable 
 
OR (95% CI) 
 
p-value 
Univariate (n = 324)    
 Depression 1.45 (0.96, 2.28) .100 
 
Age and Race  (n = 324  ) 
   
Step 1:    
 Depression 1.51 (0.96, 2.40) .077 
 Age 1.12 (1.02, 1.22) .020 
 Race 1.66 (1.02, 2.70) .042 
 
Physical activity score at visit 00 (n = 322 ) 
   
Step 2:    
 Depression 1.62 (1.01, 2.60) .046 
 Age 1.12 (1.02, 1.23) .019 
 Race 1.38 (0.83, 2.30) >.10 
 Physical activity (-) 0.76 (0.66, .88) <.001 
 
% kcal fat at visit 00 (n = 324 ) 
   
Step 2:    
 Depression 1.51 (0.95, 2.40) .078 
 Age 1.12 (1.02, 1.22) .020 
 Race 1.60 (0.98, 2.61) .061 
 % kcal fat 1.03 (0.99, 1.06) .092 
 
History / current other psychiatric diagnosis at 
visit 00 (n = 323 ) 
   
Step 2:    
 Depression 1.41 (0.87, 2.28) .161 
 Age 1.12 (1.02, 1.23) .019 
 Race 1.58 (0.97, 2.59) .068 
 Alcohol use / abuse 1.77 (0.85, 3.68) >.10 
 Drug use / abuse 1.06 (0.41, 2.74) >.10 
 Any anxiety disorder (-) 0.86 (0.48, 1.54) >.10 
1 DV = dependent variable; OR = odds ratio; CI = confidence interval 
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Table A3: (continued) 
 
 
DV: Presence of the metabolic syndrome ever from 00 – 05 1 
  
Variable 
 
OR (95% CI) 
 
p-value 
 
Antidepressant use at visit 00 (n = 324 ) 
   
Step 2:    
 Depression 1.26 (0.76, 2.08) .367 
 Age 1.12 (1.02, 1.23) .018 
 Race 1.78 (1.08, 2.92) .023 
 Antidepressants  1.90 (0.97, 3.72) .063 
 
Diabetes at visit 00 (n = 322 ) 
   
Step 2:    
 Depression 1.52 (0.93, 2.49) .092 
 Age 1.11 (1.00, 1.22) .043 
 Race 1.53 (0.90, 2.58) > .10 
 Diabetes  42.62 (5.64, 322.27) .000 
 
DV: Incident metabolic syndrome from 01 - 05  
  
Variable 
 
OR (95% CI) 
 
p-value 
 
Univariate (n = 239) 
   
    
 Depression 1.41 (0.70, 2.82) .338 
Age and Race  (n = 239 )    
Step 1:    
 Depression 1.48 (0.73, 3.00) .273 
 Age 1.08 (0.94, 1.24) >.10 
 Race 1.43 (0.68, 3.02) >.10 
1 DV = dependent variable; OR = odds ratio; CI = confidence interval 
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APPENDIX B.  DEPRESSION DEFINED AS MAJOR DEPRESSION OR ANTIDEPRESSANT USE  
 
 
 
Table B1:  Chi-square analyses showing baseline association between lifetime history / current diagnosis 
of major depression or lifetime history / current use of antidepressants and presence of the metabolic 
syndrome 
   
 
 Lifetime history / current major depression at visit 00 or lifetime history / current 
antidepressant use at visit 00 
Metabolic Syndrome 
at visit 00 
Absent 
n (%) 
Present 
n (%) 
   
Absent 211 (82.3) 125 (75.8) 
   
Present 45 (17.6) 40 (24.2) 
Chi2 * p-value 
     
Total 256 165 2.77 .096 
 
* Chi2 comparing depression to no depression 
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Table B2:  Logistic regressions showing the association of baseline major depression (lifetime history / current) or antidepressant use (lifetime 
history / current) predicting cumulative index of the metabolic syndrome at visit 05 (ever from 00 – 05) 
 
 
DV: Presence of the metabolic syndrome ever from 00 – 05 1 
  
Variable 
 
OR (95% CI) 
 
p-value 
Univariate (n = 324)    
Step 1:    
 Depression or antidepressant use 1.65 (1.05, 2.61) .031 
Age and Race  (n = 324)    
Step 1:    
 Depression or antidepressant use 1.74 (1.09, 2.78) .019 
 Age 1.12 (1.02, 1.22) .020 
 Race 1.71 (1.04, 2.79) .033 
 
DV: Incident metabolic syndrome from 01 – 05 
  
Variable 
 
OR (95% CI) 
 
p-value 
Univariate (n = 239)    
Step 1:    
 Depression or antidepressant use 1.79 (0.89, 3.60) .102 
Age and Race (n = 239)    
Step 1:    
 Depression or antidepressant use 1.88 (0.93, 3.82) .079 
 Age 1.09 (0.95, 1.24) >.10 
 Race 1.46 (0.69, 3.08) >.10 
1 DV = dependent variable; OR = odds ratio; CI = confidence interval 
 Table B3.  Cox proportional hazard model of the association between baseline major depression or 
antidepressant use (lifetime history / current) and risk of developing the metabolic syndrome through visit 
05      
 
 
Model  
(n = 336) 
Predictor Variable Hazard Ratio (95% 
CI) 1,2 
p-value 
1 Lifetime history / current MD or use of 
antidepressants at visit 00 
1.73 (0.91, 3.26) 0.092 
    
2 Lifetime history / current MD or use of 
antidepressants at visit 00 
1.79 (0.94, 3.38) 0.074 
 Age at visit 00 1.12 (0.99, 1.26) 0.076 
    
3 Lifetime history / current MD or use of 
antidepressants at visit 00 
1.80 (0.95, 3.42) 0.071 
 Age at visit 00 1.12 (0.99, 1.26) 0.073 
 Race (Black) 1.13 (0.58, 2.22) >.10 
    
4 Lifetime history / current MD or use of 
antidepressants at visit 00 
1.82 (0.96, 3.46) 0.067 
 Age at visit 00 1.12 (0.99, 1.26) 0.075 
 Race (Black) 1.12 (0.57, 2.21) >.10 
 Menopausal Status 0 (early perimenopause) 0.82 (0.43, 1.56) >.10 
    
6 Lifetime history / current MD or use of 
antidepressants at visit 00 
1.77 (0.94, 3.36) 0.079 
 Age at visit 00 1.13 (0.99, 1.28) 0.057 
 Race (Black) 0.90 (0.45, 1.81) >.10 
 Physical activity score at visit 00 0.80 (0.66, 0.99) 0.038 
1 CI = confidence interval; MD = major depression 
2 Results of full multivariate model controlling for age, race, menopausal status, and physical activity were 
similar. 
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 APPENDIX C.  WAIST CIRCUMFEENCE AND FREQUENCY OF DEPRESSIVE EPISODES 
 
 
 
Table C1.  Mean waist circumference at follow-up visit 05 according to number of depressive episodes 
(major depression or subthreshold recurrence) across study period (00 – 05) 
 
 
Total number of depressive 
episodes 
Number of participants Waist circumference at visit 05 
Mean (SD) 1 
   
0 177 88.72 (14.83) 
1 55 88.17 (13.98) 
2 33 91.72 (19.90) 
3 24 95.43 (19.12) 
4 13 93.45 (10.15) 
5 8 100.63 (16.75) 
6 3 87.60 (7.52) 
1 SD = standard deviation 
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FOOTNOTES 
 
1Analyses for the metabolic syndrome were also conducted with diabetes defined only according to self-
reported use of “insulin or pills for sugar in her blood”.  There were no differences in results when 
diabetes was defined in this manner.     
2Standardized Pearson residuals were calculated and graphed to identify potential outliers in the data 
(Hardin & Hilbe, 2003; Rabe-Hesketh & Everitt, 2004).  Analyses were then rerun excluding participants 
with Pearson residuals greater than 4 (n=1) and subjects with the most extreme values of WC (top 2%).  
Results of these analyses did not differ from those described with the full sample.  Plots of residuals 
against predicted scores of WC showed no violations of normality, heteroscedasticity, or nonlinearity 
(Hardin & Hilbe, 2003; Rabe-Hesketh & Everitt, 2004).  Sensitivity analyses were run with the 264 women 
with complete data for depression and WC at every visit to explore the potential effect of missing data on 
the above model; the negative association between depression and WC remained significant (p < .01).  
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